Research workspace

Clinical trials, registry fields, genomics, health equity, and patient empowerment baselines — public data labeled cited_* or affinity. Heuristic crosswalks stay here; they do not feed deal economics, comps, or dual-source badges.

Oncology Claim-Integrity Monitor compares dated public claims with cited evidence. It is separate from valuation and exit-similarity panels.

Burden–Capital Opportunity Context

WEF/BCG Figure 3: sourced population burden and historical funding context across women's-health therapeutic areas. A research heuristic for diligence questions — not enterprise value. Widest contrast is outside the traditional bucket (CVD, metabolic). Burden columns pending IHME GBD 2023.

Burden–Capital Opportunity Context

Capital raised vs. disease burden across women's-health therapeutic areas (WEF/BCG Figure 3, 2020–2025). The sharpest gap: cardiovascular disease — 11 funding events and ~$10M raised, against the leading cause of death in women — a misclassification Lacuna exists to correct.

This view compares sourced population-level burden and historical funding context. It is a transparent research heuristic for identifying diligence questions; it does not estimate enterprise value, clinical benefit, commercial success, investment returns, or probability of exit.

Affects women uniquelyAffects women differentlyAffects women disproportionatelyCapital raised

Burden: pending IHME GBD 2023 — chart sorted by funding events until DALY data lands.

Funding crosswalk (6 aligned · 4 partial · 6 unmapped)

This chart uses WEF/BCG macro funding (2020–2025, all WH-tagged flows). The context view below uses US GBD 2021 burden + WEF-aligned VC for cardiovascular ($10M) and metabolic ($4M) areas, plus Rock Health / PitchBook FemTech estimates elsewhere (2019–2024). Capital figures differ by design — they answer different questions, and neither series is an enterprise value.

WEF area	Crosswalk area	WEF capital	Crosswalk capital	Gap score
Women's cancers	Breast Health & Oncology	$127.0B	$1.4B	10/100
Reproductive health	Fertility & IVF	$22.0B	$2.1B	1/100
Maternal health	Maternal Health	$9.0B	$850M	5/100
Generic women's health	Unmapped	$11.0B	—	—
Mental health	Women's Mental Health	$1.4B	$920M	15/100
Endometriosis	Endometriosis & Pelvic Pain	$1.7B	$310M	16/100
PCOS	PCOS & Metabolic Reproductive	$100M	$420M	10/100
Infectious diseases	Unmapped	$400M	—	—
Endocrine disorders	Unmapped	$2.2B	—	—
Urological disorders	Sexual Health & Wellness	$30M	$190M	7/100
Menstrual health	Unmapped	$100M	—	—
Cardiovascular disorders	Women's Cardiovascular Disease	$10M	$10M	100/100
Metabolic disorders	Women's Metabolic Disorders	$4M	$4M	84/100
Menopausal health	Menopause & Midlife Health	$1.0B	$280M	13/100
Neurological disorders	Unmapped	$10M	—	—
MSK & pain disorders	Unmapped	$5M	—	—

Crosswalk-only areas (no WEF row): Contraception & Family Planning, Precision Medicine & Genomics.

Endometriosis ecosystem coverage (45 for-profit cos. w/ funding status · 1 in verified dataset)

Crunchbase Pro search returned 409 results. Included 45 for-profit product companies with Crunchbase funding or fundraising status. Excluded 18 nonprofits, 154 clinical service providers, and 129 entries without verifiable funding fields.

Crunchbase search

409

Included (funded)

Verified overlap

Updated

2026-06-28

Company	Category	Funding	Verified
Context Therapeutics#5,749 Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context's lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.	Pharma	IPO	—
Organon#5,808 Organon develops and provides medicines and health solutions focused on women's health, biosimilars, and established brands. The company offers treatments for contraception, fertility, menopause, and conditions such as endometriosis, along with therapies addressing cardiovascular and respiratory diseases through its established portfolio.	Pharma	IPO	—
Xella Health#7,024 Crunchbase - crunchbase.com/organization/xella-health	Digital health	Early Stage Venture	—
EndoGene.Bio#9,650 Endogene.bio was founded to solve the lack of molecular data that keeps endometriosis a clinical black box. By analyzing key cells in menstrual blood, the company delivers tissue-level insights with the convenience of a liquid biopsy.	Diagnostics	Seed · $3.1M	—
Visana Health#10,688 Visana Health offers a digital health program focused on improving the quality of life for women who suffer from severe menstrual pain.	Digital health	Early Stage Venture	—
Gesynta Pharma#13,803 Gesynta Pharma is a clinical stage pharmaceutical company, developing a portfolio of compounds which inhibit the pro-inflammatory enzyme mPGES-1. Gesynta Pharma's most advanced drug candidate is vipoglanstat (GS-248), in clinical Phase 2 development as a non-hormonal treatment for endometriosis.	Therapeutics	Early Stage Venture	c86
Calla Lily Clinical Care#19,801 Calla Lily Clinical Care is a women's health focused B-Corp that has developed the proprietary Callavid platform for intravaginal drug delivery.	Medical device	Early Stage Venture	—
Opal Therapeutics#24,549 Opal Therapeutics is building a uterine organoid-based discovery platform to address critical gaps in reproductive health R&D. Conditions like endometriosis and fibroids affect over 100 million women worldwide.	Platform	Grant · $0.275M	—
DotLab#25,451 DotLab provides biomarkers and the power of machine learning to deliver the first non-invasive tool to diagnose endometriosis.	Diagnostics	Early Stage Venture · $12.65M	—
FimmCyte#42,844 FimmCyte develops a novel disease modifying treatments for fibro-inflammatory diseases, starting with Endometriosis.	Therapeutics	Early Stage Venture	—
ELANZA Wellness#43,349 ELANZA Wellness is a virtual chronic care platform built for people with endometriosis.	Digital health	Early Stage Venture	—
Endometriosis#44,490 Endometrics is a creator of a genetic biomarker for the early identification of endometriosis.	Diagnostics	Early Stage Venture	—
Scanvio#44,597 Scanvio offers AI-augmented ultrasound software for faster endometriosis diagnosis.	Diagnostics	Early Stage Venture	—
Afynia Laboratories#46,246 Aima Laboratories is a women's health healthcare company working on the first non-invasive endometriosis diagnostic tool for the market.	Diagnostics	Early Stage Venture	—
FemmePharma Global Healthcare#69,786 FemmePharma Global Healthcare, Inc., a pharmaceutical company, engages in developing drugs for diseases and disorders affecting women internationally including endometriosis.	Pharma	M&A	—
Nura Health#70,929 Nura Health is a molecular diagnostics firm that is improving women's health by creating and distributing innovative non-invasive tests.	Diagnostics	Early Stage Venture	—
Syrona Health#74,369 Syrona Health is a digital health solution for personalised gynaecology across life-stages starting from Menstrual health to Menopause. We cover Endometriosis, PCOS, Fertility, Parenthood and Menopause.	Digital health	Early Stage Venture	—
Maipl Therapeutics, Inc.#93,456 Maipl Therapeutics is developing radically different, first-in-class medicines to treat endometriosis and other diseases.	Therapeutics	Early Stage Venture	—
EndoCure#93,795 EndoCure is a endometriosis diagnostic, and a novel robotic AI-powered ultrasound is revolutionizing the field.	Diagnostics	Early Stage Venture	—
Kranus Health#98,573 Kranus Health is building the world's first AI-enabled gender medicine platform with a pipeline extending into endometriosis.	Digital health	Early Stage Venture	—
Sur180 Therapeutics#99,791 We are a women's owned startup focusing on new therapeutic approaches to gynecological conditions. Our primary focus is endometriosis.	Therapeutics	Early Stage Venture	—
Endo app#101,481 Endo App is a CE-certified interactive, smartphone-based medical gadget for multimodal pain management and endometriosis therapy.	Digital health	Early Stage Venture	—
Temple Therapeutics#101,713 Temple Therapeutics creates and develops therapies for orthopedics, oncology, and endometriosis patients.	Therapeutics	Early Stage Venture	—
Endodiag#106,834 Endodiag specializes in the development of products and services that improves the diagnosis of endometriosis.	Diagnostics	Early Stage Venture	—
MEDAI#107,448 MEDAI is a technology company with OVARIANA, a digital health platform focused on endometriosis awareness and gynecological symptom tracking.	Platform	Early Stage Venture	—
Belle Health#118,352 Belle Health AI Technologies is a pioneering femtech startup addressing endometriosis and hormonal health needs with the Belle Ring.	Medical device	Early Stage Venture	—
Neurocrine Biosciences#127,038 Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of endocrine-related diseases including endometriosis.	Pharma	IPO	—
Memmzy Health#129,387 Memmzy Health is a Fem-HealthTech company with AI-driven predictions for conditions like endometriosis.	Digital health	Early Stage Venture	—
Evestra Onkologia#164,539 Evestra Onkologia engages in Research and Development pertaining to oncology and endometriosis assets.	Pharma	Early Stage Venture	—
Pyrefin#166,568 Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists with efficacy in endometriosis.	Therapeutics	Early Stage Venture	—
Cicero Diagnostics#169,519 Cicero Diagnostics is dedicated to clinical assays for understudied women's diseases including endometriosis under ReceptivaDx.	Diagnostics	Early Stage Venture	—
NALU#186,759 NALU offers personalized digital therapies for menstrual disorders including endometriosis.	Digital health	Early Stage Venture	—
Meliodays Medical#195,928 Meliodays Medical develops targeted, non-hormonal drug delivery systems for chronic menstrual pain including endometriosis.	Medical device	Early Stage Venture	—
Diamens#317,051 Diamens is a company focused on femtech that develops a non-invasive menstrual blood-based molecular diagnostic to detect women-specific diseases like endometriosis.	Diagnostics	Early Stage Venture	—
Valeo Medical#321,584 Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis.	Diagnostics	Early Stage Venture	—
Viramal#328,420 Viramal is an emerging specialty pharmaceutical company with a women's health clinical development pipeline including treatments for endometriosis.	Pharma	Early Stage Venture	—
July Health#356,321 July Health is a digital health platform delivering proactive end-to-end care including endometriosis management across Canada.	Digital health	Early Stage Venture	—
Meditrina Pharmaceuticals#1,306,906 Meditrina Pharmaceuticals, Inc. identifies and repurposes already marketed therapies for gynecologic conditions such as endometriosis and uterine fibroids.	Pharma	Closed · $4.5M	—
FemXX Health#1,947,229 FemXX Health helps women with endometriosis find insights into treatments via a technology platform.	Digital health	Closed · $0.1M	—
ENDODIAGNOSIS INC.#2,797,679 EndoDiagnosis provides non-invasive ENDOSURE diagnostic testing for endometriosis.	Diagnostics	Early Stage Venture · $0.15M	—
Milestone Gynomics#3,202,128 Milestone Gynomics is an early stage startup developing a non-invasive AI-driven blood test for accurately diagnosing endometriosis.	Diagnostics	Seed · $0.034M	—
AEVA HEALTH LTD#4,119,615 Aeva Health offers a women's health platform that combines digital tools with access to specialist practitioners for conditions such as PCOS, thyroid disorders, endometriosis, IBS and other hormone and gut-related issues.	Digital health	Early Stage Venture · $0.13M	—
3CPM LTD#4,429,533 3CPM develops diagnostic healthcare technologies focused on non-invasive evaluation of gastrointestinal and pelvic disorders including electroviscerography-based solutions for endometriosis diagnostics.	Diagnostics	Grant	—
Theramex Deutschland#4,445,171 Theramex Deutschland is a pharmaceutical company that focuses on medicines for women's health including treatments for endometriosis and uterine fibroids.	Pharma	Private Equity	—
Mabpro, A.s.#4,590,084 Mabpro develops cancer immunotherapies and companion diagnostics and conducts research into CA IX-related mechanisms in endometriosis.	Therapeutics	Early Stage Venture · $2.7M	—

Crunchbase Pro text search paste parsed with ingest-crunchbase-text format. Included only for-profit product companies with Crunchbase fundingStatus, fundraisingStatus, totalFunding, or lastFundingType (CSV or verified registry). Clinical service providers, hospitals, and nonprofits excluded.

Endometrial cancer ecosystem coverage (22 for-profit cos. w/ funding status · 4 in verified dataset)

Crunchbase Pro search returned 57 results. Included 22 for-profit product companies with Crunchbase funding or fundraising status. Excluded 1 nonprofits, 14 clinical service providers, and 27 entries without verifiable funding fields.

Crunchbase search

Included (funded)

Verified overlap

Updated

2026-06-28

Company	Category	Funding	Verified
MiMARK#12,168 MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK's first objective is to improve endometrial cancer diagnosis.	Diagnostics	Early Stage Venture · $4.5M	—
Sola Diagnostics#36,304 Sola Diagnostics' WID-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. Private equity investments totaling €3.4M and NIHR GBP 2.2M grant support market access.	Diagnostics	Private Equity · $3.7M	—
Madera Therapeutics#474,183 Madera Therapeutics is advancing TR compounds that activate mitochondrial protease ClpP with activity across endometrial cancer and other drug-resistant solid tumors.	Therapeutics	Early Stage Venture	—
Xoft#548,264 Xoft, Inc. develops electronic brachytherapy systems for radiation oncology including vaginal applicators used to treat endometrial cancer.	Medical device	M&A	—
Swisssurgical#3,163,906 Swisssurgical develops a medical device for guided endometrial biopsy for the detection of uterine cancers.	Medical device	Early Stage Venture	—
Idoman#3,376,185 Idoman operates in the wholesale industry, focusing on medical devices. The company manufactures and distributes the Thermablate Endometrial Ablation System, designed to adapt to various uterine cavity shapes and sizes. It also offers the Wing Needle for hysteroscopic procedures. Idoman serves as a distributor for these products, collaborating with authorized resellers to ensure their availability in different regions.	Medical device	Private Equity	—
Keytruda#3,480,656 Keytruda develops and markets pembrolizumab, a monoclonal antibody immunotherapy used to treat a range of cancers. The drug targets the PD‑1 pathway to help T cells detect and attack tumor cells. It is indicated for non–small cell lung cancer, melanoma, head and neck squamous cell carcinoma, urothelial carcinoma, gastric and esophageal cancers, cervical cancer, renal cell carcinoma, endometrial carcinoma, cutaneous squamous cell carcinoma, triple‑negative breast cancer, and MSI‑H/dMMR solid tumors. Keytruda also provides patient education, treatment guides, and access support resources for people receiving the therapy.	Pharma	IPO	—
MIRFLOW LTD#3,544,284 MIRFLOW develops a rapid blood-based genomic testing platform for early detection and recurrence monitoring of endometrial cancer. Funding from the EQT Foundation Women's Health Grant supports prototype validation.	Diagnostics	Grant	—
Swift Biotechnology#3,579,346 Swift is developing state of the art technologies that will save lives and save their health care system billions of dollars in unnecessary treatments made necessary due to late diagnosis. Swift is initially targeting development of screening modalities for endometrial and ovarian cancer. Their company is also pursuing plans for development of screens for other cancers and delivery systems which can transport treatment regimens by novel means in a site-specific manner. Swift Biotechnology is partnering with the University of South Alabama's Mitchell Cancer Institute, the premier cancer research facility on the Gulf Coast, and their offices are located on the premises.	Diagnostics	Early Stage Venture · $1.1M	—
Thermablate#3,753,344 Thermablate is a fully-automated, portable medical device used to carry out global endometrial ablation (GEA). It helps treat pre-menopausal women suffering from heavy menstrual bleeding.	Medical device	Private Equity	—
Utepreva#3,897,773 Utepreva develops and commercializes single-use endometrial sampling devices for uterine cancer evaluation and early detection. The company focuses on the Utepreva Endometrial Sampler, a patented, FDA 510(k)-cleared device designed for rapid, in-office uterine tissue collection. The sampler combines suction, disruption, and absorption to retrieve both cellular and fluid-based samples suitable for diagnostic analysis. Utepreva targets clinicians and healthcare providers looking to integrate uterine sampling into routine clinical workflows without specialized equipment or operating room access. The company manufactures the device and works with distribution partners that manage national sales and deployment across clinical and healthcare networks. Its offerings are positioned for use in women's health and oncology diagnostics settings to address the lack of standardized screening approaches.	Medical device	Early Stage Venture	—
Celvia CC AS#4,159,380 Celvia develops genetic tests and laboratory services focused on reproductive medicine, prenatal screening and food safety. The company offers assays such as NIPTIFY for non-invasive prenatal screening, beREADY for endometrial receptivity assessment and PGT-A testing to support in vitro fertilization decisions. Its portfolio also includes InvisibleMi tests for genital tract microbiome profiling and CLARITY testing for chromosomal causes of pregnancy loss. Celvia extends its molecular diagnostics expertise to food safety through honey metagenomic DNA analysis to characterize honey composition and detect adulteration. The organization conducts research and development projects that integrate genomics, bioinformatics and clinical collaboration to create science-based diagnostic solutions for patients, clinicians and businesses.	Diagnostics	Grant	—
Igenomix#4,214,095 Igenomix provides reproductive genetic testing services focused on fertility, IVF, and prenatal care. The company operates as a research‑driven laboratory group that collaborates with IVF clinics and fertility doctors to develop genetics‑based tests that support all stages of the reproductive journey. Its portfolio includes preimplantation genetic testing such as PGT‑A, PGT‑M, PGT‑SR and related embryo assessment tools, endometrial receptivity and microbiome tests like ERA, EMMA, ALICE and EndomeTRIO, and non‑invasive embryo evaluation such as EMBRACE. Igenomix also offers carrier screening (CGT), sperm analysis tests (SAT), miscarriage analysis (POC), and non‑invasive prenatal screening tests like NACE. These services are designed for healthcare professionals and patients seeking to understand infertility causes, reduce genetic disease risk, and support healthy pregnancy outcomes.	Diagnostics	M&A	c33
Normedi#4,506,686 Normedi develops and distributes medical devices and consumables for gynecological surgery. The company focuses on minimally invasive solutions for hysteroscopy, endometrial ablation, laparoscopy, and colposcopy, including tissue removal systems, adhesion barriers, scopes, and fluid management equipment. Normedi supplies products such as NovaSure V5 endometrial ablation, the MyoSure tissue removal suite, Oxiplex adhesion barrier gels, and a range of instruments, optics, and accessories. It serves gynecologists, hospitals, and clinics by offering devices for office and operating-room procedures that address abnormal uterine bleeding, intrauterine pathologies, and adhesion prevention. Through Normedi Education, it also delivers training, clinical information, and procedure-focused resources for healthcare professionals in gynecology.	Medical device	M&A	—
Theoreo#4,528,974 Theoreo develops metabolomics-based diagnostics including the Medea Test for early detection of endometrial cancer using blood-based metabolic signatures.	Diagnostics	Grant	—
Foundation Medicine Foundation Medicine provides comprehensive genomic profiling guiding precision oncology including endometrial and gynecologic cancers.	Diagnostics	M&A	c38
Context Therapeutics Context Therapeutics develops progesterone receptor antagonists for hormone-responsive cancers including endometrial and ovarian cancer.	Pharma	IPO	—
Immunomedics Immunomedics (Gilead) ADC oncology platform — Trodelvy and broader precision oncology portfolio.	Pharma	M&A · $21000M	c58
Seagen Seagen ADC oncology platform including Tukysa and Tivdak for women's cancers.	Pharma	M&A	c56
Corcept Therapeutics Corcept develops relacorilant, a selective glucocorticoid receptor modulator in Phase 3 for endometrial cancer.	Pharma	IPO	—
Natera Natera provides cfDNA diagnostics including Signatera MRD and women's health oncology applications.	Diagnostics	IPO	—
Guardant Health Guardant Health liquid biopsy platform for oncology treatment selection and monitoring.	Diagnostics	IPO	—

Crunchbase Pro text search paste plus verified funding registry. Included only for-profit product companies (diagnostics, therapeutics, devices, digital health) with Crunchbase fundingStatus, fundraisingStatus, totalFunding, or lastFundingType. Gynecologic oncology clinics, hospitals, and nonprofits excluded.

Sources

[WEF/BCG 2026] World Economic Forum & Boston Consulting Group. Women's Health Investment Outlook 2026. Figure 3 — funding events and capital raised by therapeutic area, 2020–2025. PitchBook, CapIQ, Crunchbase. Link

[IHME GBD 2023] Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2023. Burden columns pending ingestion. Link

[AOA Dx — Follow the Exits (2026)] AOA Dx. "Follow the Exits: Why Women's Health Is a Smart Bet in Healthcare." Jan 13, 2026; exit totals via Forbes (Geri Stengel). Link

Stage funding median

Burden–Capital Opportunity Context continued: US GBD 2021 burden and historical VC context — WEF-aligned for CVD/metabolic. Dollar output is the verified-dataset stage funding median only; editorial Rock Health / PitchBook medians and gap multipliers are not used as a price.

Burden–Capital Opportunity Context

Each bar shows how underfunded a disease area is relative to its societal burden (DALYs[1], prevalence[3], mortality[2]). VC deployment from Rock Health[5] & PitchBook[6] 2019-2024.

Women's Cardiovascular Disease

100

Women's Metabolic Disorders

Endometriosis & Pelvic Pain

Women's Mental Health

Menopause & Midlife Health

Precision Medicine & Genomics

PCOS & Metabolic Reproductive

Breast Health & Oncology

Contraception & Family Planning

Sexual Health & Wellness

Maternal Health

Fertility & IVF

Gap score 1–100 (higher = more underfunded relative to burden)[1,5,6]. Minimum score is 1 (lowest in dataset), not zero.

Context inputs

Therapeutic areaFunding stage

Total funding raised: $15MClinical evidence

Endometriosis & Pelvic Pain

Limited gap

US DALYs / yr: 3.8M[1]

US prevalence: 6.5M women[3]

NIH funding: $60M/yr[4]

VC deployed (2019-24): $310M[5,6]

VC / 1k DALYs: $0.08M[1,5]

Neglect score: 5/5

FDA Priority Review eligible; diagnosis delay 1–5 years depending on pathway

Sources

[1] GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries. Lancet. 2024;403(10440):2133–2161.

[4] NIH Research Portfolio Online Reporting Tools (RePORTER). Fiscal Year 2023 Funding by Disease/Condition. Bethesda, MD: National Institutes of Health, 2023.

[5] Rock Health. 2024 Digital Health Funding Database — Women's Health Segment. San Francisco, CA: Rock Health, 2024. Covers venture funding rounds 2019–2024.

[7] Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382(13):1244–1256. Prevalence 6–10% of reproductive-age women; 7-year average diagnosis delay widely cited in ACOG Practice Bulletin 114.

[13] Bonafede M, et al. Healthcare resource utilization and costs associated with endometriosis diagnosis delay in the United States. J Manag Care Spec Pharm. 2020;26(7):842–851. PMID 31960340. Pre-diagnosis costs: $21,489 (≤1-yr delay) to $34,460 (3–5-yr delay) per patient over 60 months; 12.5% of all-cause costs attributable to endometriosis.

Dataset stage funding median

Verified-dataset median total funding at this stage — not a gap-adjusted exit price, TAM multiple, or editorial PitchBook range.

Low

$19M

Mid

$19M

High

$19M

Stage comparable (median total funding): $19M. Gap scores below stay descriptive and are not applied as a premium.

Context factors

Burden-Capital Gap-1.4

Gap score 16/100 — $0.08M VC per 1k DALYs

Clinical Evidence0.0

pilot

Reimbursement Pathway-0.5

No reimbursement yet — key de-risking milestone

Health Equity Angle0.0

Single-population focus

Platform Potential0.0

Single-indication product

Neglect Score (area)+1.0

5/5 — highly underserved

Payer Coverage-0.5

No reimbursement yet; sector avg 50% payer coverage — partial coverage; prior-auth risk

Provider Access0.0

Requires MIS-trained gynecologist; surgical expertise concentrated in academic centers. Pre-diagnosis healthcare costs $21,489–$34,460 per patient over 60 months (Bonafede et al. 2020, PMID 31960340); 35.3% of patients wait 3–5 years for diagnosis, 12.5% of all their healthcare costs are endometriosis-related during that period. Depression SMD 0.71, anxiety SMD 0.60 vs. healthy controls (PMID 34077695).

Stage comparable is the verified-dataset median total funding raised by stage. Gap scores and factor notes stay descriptive — they are not applied as a price, premium, or TAM multiple. Disease burden from GBD 2021 and CDC WONDER 2022. Not a financial model or investment advice.

Sources

[4] NIH Research Portfolio Online Reporting Tools (RePORTER). Fiscal Year 2023 Funding by Disease/Condition. Bethesda, MD: National Institutes of Health, 2023.

[5] Rock Health. 2024 Digital Health Funding Database — Women's Health Segment. San Francisco, CA: Rock Health, 2024. Covers venture funding rounds 2019–2024.

[6] PitchBook Data. Women's Health & FemTech VC Deal Flow Report 2019–2024. Seattle, WA: PitchBook, 2024. Deal counts and disclosed round values.

Women's health exit landscape

AOA Dx Follow the Exits (Jan 2026): 276 exits and $100B+ in M&A/IPO value (2000–2025), often mis-tagged in PitchBook. Compared honestly to Lacuna's curated deal set.

Women's health exit landscape (macro research)

AOA Dx's Follow the Exits report (Jan 2026) manually re-tags acquisitions and IPOs often filed under diagnostics or oncology — surfacing exits investors' databases miss. Lacuna's 51 verified deals ($125.2B all-scope disclosed) are a curated educational subset, not this 276-exit universe.

Source universe

AOA Dx: broad historical women's-health exit research universe with its own definitions and methods.
SVB: current sector-level healthcare funding and exit context, time-bound to H1 2026 data.
Lacuna: curated public-source M&A sample, not a census.

These sources are complementary context sets and are not directly comparable as counts, values, returns, or coverage universes.

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

$100B+

Exits 2000–2025 (AOA Dx)

276

Exit count (M&A + IPO)

Deals over $1B

91%

M&A share of exits

AOA exit concentration (2000–2025)

Gynecologic health$29.6B
Oncology$24B

Nearly $19B from gynecologic oncology alone (AOA Dx).

$27B in transactions in 2025 alone — largest year on record (AOA Dx).

Kearney private investment (Since 2020; Kearney analysis cited in Forbes (Jan 2026).)

$34B total private capital
$21B women-specific conditions (fertility, women's cancers)
$13B disproportionately affecting women (CVD, Alzheimer's, autoimmune, mental health)
$7.6B diagnostics & digital health (2,000+ deals tracked)

Repeat acquirers in Forbes coverage: Hologic, Roche, LabCorp, Abbott, CooperSurgical.

Nearly half of all exits occurred in the past five years (AOA Dx, via Forbes Jan 2026).

Sources

AOA Dx — Follow the Exits (2026) — AOA Dx. "Follow the Exits: Why Women's Health Is a Smart Bet in Healthcare." Released at JPMorgan Healthcare Conference, San Francisco, Jan 13, 2026.
Forbes (Jan 2026) — Stengel, G. Women's Health Exits Surpassed $100 Billion. Forbes, Jan 13, 2026.
Kearney (via Forbes) — Kearney global consultancy analysis — 2,000+ private deals since 2020; $34B women's-health investment split by condition category. Cited in Forbes (Jan 2026).

RH Capital portfolio

Funds I & II (Foreground Capital): cited funding and exit notes for portfolio companies on rhcapital.vc — overlaid on the network graph as RH Capital.

RH Capital portfolio (Foreground Capital)

RH Capital Funds I and II are managed by Foreground Capital (foreground.vc). Metrics below are from press releases and trade press — not Lacuna verified M&A deals unless noted as an exit. Toggle the RH Capital overlay on the network graph to highlight these companies.

Portfolio companies

With cited funding total

$472.2M

Sum of cited funding totals

Documented exits (undisclosed terms)

Company	Focus	Funding	Exit / valuation
AOA Dx	Oncology diagnostics	$24M	—
Bloomlife	Maternal digital health	—	—
Cadence OTC	Contraception	$35M	—
Cayaba Care	Maternal health equity	$15M	—
Cirqle	Contraception	—	—
Cofertility	Fertility	$16M	—
Contraline	Male contraception	$127M	—
Eli Health	Hormone diagnostics	$20M	—
Evvy	Diagnostics	$19M	—
Gesynta Pharma	Endometriosis therapeutics	—	—
Mae	Maternal health equity	$1.3M	—
Millie	Maternal care delivery	$19M	—
Neuspera	Pelvic health device	—	—
Novocuff	Preterm birth device	—	—
Nurx	Digital pharmacy	$110M	Thirty Madison (Ro parent) · terms undisclosed
Ocon Med	Drug delivery	—	—
Ovia Health	Digital maternal health	$23.4M	LabCorp · terms undisclosed
Planera	Period care	$9.5M	—
Raydiant Oximetry	Maternal-fetal monitoring	—	—
Seven Starling	Perinatal mental health	$22M	—
Testmate Health	STI diagnostics	$6M	—
Twenty Eight Health	Reproductive telehealth	$25M	—
Vitra Labs	Fertility technology	—	—
YourChoice Therapeutics	Contraception therapeutics	—	—

RH Capital portfolio — RH Capital — Portfolio page (Funds I & II, Foreground Capital).
Foreground Capital — RH Capital Funds I and II are managed by Foreground Capital (foreground.vc).

Space research → trial → transaction

Space-linked women's health assets scored on a fixed pipeline (research signal → space validation → Earth trial → company → verified M&A). Gap matrix and LLM analyst expose where research never becomes a deal.

Space → trial → transaction gaps

Curated public citations of space-linked women's health research joined to Lacuna's verified M&A dataset. Pipeline stages are descriptive evidence flags — not investment advice, clinical recommendations, or forecasts.

Research assets

Commercial gaps

Touch verified deals

Physiology-only

Pipeline funnel (furthest stage)

Research signal

Space validation

Earth trial signal

Company in Lacuna dataset

Verified M&A transaction

Gap matrix (assets reaching stage)

Area	research	space	earth	company	transaction	Gaps
Breast oncology	2	2	2	2	2	0
Contraception / menstrual suppression	2	1	2	1	1	1
Fertility / ovarian function	2	0	2	0	0	2
Gynecologic oncology	2	2	2	2	2	0
Menopause-adjacent (bone / hormones)	2	2	2	1	1	1
Menstrual devices	1	0	1	0	0	1
Osteoporosis (postmenopausal)	1	1	1	0	0	1

BP-NELL-PEG (NELL-1 osteoporosis therapeutic)

Therapeutic tested in space (animal/cell efficacy)

Commercial gap

research signalspace validationearth trialcompanytransaction

Preclinical only — no approved human product.

Combined oral contraceptives (astronaut menstrual suppression)

Operational pharma used by women in flight (not a product trial)

research signalspace validationearth trialcompanytransaction

Linked: Organon

Deals: Organon (via Merck spinoff) ← Alydia Health; Organon ← Forendo Pharma; Organon ← Dermavant Sciences

Operational use ≠ product development pipeline.

Pembrolizumab (Keytruda) microgravity crystallization

Formulation / delivery informed by microgravity

research signalspace validationearth trialcompanytransaction

Linked: Organon

Deals: Organon (via Merck spinoff) ← Alydia Health; Organon ← Forendo Pharma; Organon ← Dermavant Sciences

Formulation/delivery win — not a new WH mechanism of action.

MicroQuin TMBIM6 small-molecule (breast/ovarian models)

Formulation / delivery informed by microgravity

research signalspace validationearth trialcompanytransaction

Linked: Ro, Ro

Deals: Ro ← Modern Fertility; Ro ← Nurx

No public late-stage CT.gov program under TMBIM6 in Lacuna's live search defaults.

NASA Rodent Research-20 / female reproductive physiology

Physiology / device / cell study — no therapeutic candidate

Commercial gap

research signalspace validationearth trialcompanytransaction

Physiology gap: risk characterized, no space-tested therapeutic for ovarian protection.

Axiom ORION — ovarian granulosa/theca cells

Physiology / device / cell study — no therapeutic candidate

Commercial gap

research signalspace validationearth trialcompanytransaction

No path from cell study to Lacuna company or deal.

AstroCup — menstrual cups in spaceflight conditions

Physiology / device / cell study — no therapeutic candidate

Commercial gap

research signalspace validationearth trialcompanytransaction

Device, not pharma. No femtech menstrual-cup company in verified M&A set.

Gap analyst (LLM)

Grounded only in the pipeline JSON above. Uses Vercel AI Gateway model spacexai/grok-4.3 when configured; otherwise a deterministic summary.

Clinical Trials Worth Watching

Live oncology, pelvic health, fibroids, fertility, contraception, maternal health, sickle cell, GRAIL MCED, NCI HER2/pertuzumab, and platinum-resistant ovarian searches plus a cited domestic sample-size catalog.

Clinical Trial Tracker

Live ClinicalTrials.gov registry fields. Model-derived trial scores are not displayed because Lacuna does not currently ship a version trained on a documented, versioned ClinicalTrials.gov cohort.

Live API

NCI trials — breast and gynecologic oncology, hereditary cancer, genomic screening

Total trials

Shown

Not reported

Enrollment (0 of 0 shown report)

Phases represented

Phase distribution

Status breakdown

Top sponsors

No data

Recent trials

No ClinicalTrials.gov matches were found for this current query.

Data sourced from ClinicalTrials.gov API v2. Results reflect the most recent data available. This is not a substitute for IQVIA i3 or other institutional trial intelligence platforms — trial counts may differ due to sponsor matching, condition indexing, and query scope. A zero result means no matches for the current live filter, not proof that no trials exist in the broader market.

Domestic research sample universe

Cited US cohort sizes from NIH, Harvard affiliates, and MIT/Broad — PCOS, BRCA, sickle cell, lupus, and population genomics. Rows stay labeled cited_* or illustrative context — not deal comps.

Trial search is live; cohort sample sizes are static citations. Model-derived trial scores are not displayed because Lacuna does not currently ship a version trained on a documented, versioned ClinicalTrials.gov cohort.

Registry fields

ClinicalTrials.gov and openFDA fields on verified targets when a lookup returns them. Missing records stay blank. They are not a clinical-validation score.

Registry fields on verified targets

ClinicalTrials.gov and openFDA fields are shown when a lookup returns them. A missing lookup is omitted. It is not a score, a GRADE rating, or a clinical-validation claim.

Research integrity: context on this panel is not a score, a valuation, an acquisition prediction, or a market census.

Lacuna does not turn report context into a company score.
Lacuna does not turn a gap into a valuation.
Lacuna does not turn historical exits into an acquisition prediction.
Lacuna does not turn research representation into clinical validation.
Lacuna does not turn a qualitative expert assessment into an objective metric.
Lacuna does not turn unavailable data into 0.
Lacuna does not turn unknown into a negative finding.
Lacuna does not turn a static curated sample into a market census.
Lacuna does not turn AI opportunity framing into an AI performance claim.
Lacuna does not turn a polished dashboard into evidence that does not exist.

No trial or FDA record is attached to these targets in the current lookup.

Sort by:

Disease-linked genetic markers

PCOS, hereditary breast cancer, sickle cell (HBB), lupus, and Lynch syndrome — queryable variant summaries with HIPAA/GDPR de-identification by default.

Patient empowerment baseline

HLTH Foundation / Outcomes4Me (2022): cited empowerment gaps indexed 0–100 and crosswalked to Lacuna portfolio by sector + keyword affinity. GET /api/research/patient-empowerment.

Patient empowerment baseline (breast cancer, 2022)

Lacuna crosswalks cited HLTH/Outcomes4Me gaps to the verified portfolio — we do not measure live patient empowerment. Sector and keyword joins stay labeled affinity and do not feed deal economics, comps, or dual-source badges.

Cited (survey 2022)Portfolio crosswalk (heuristic)

Data freshness: Static HLTH/Outcomes4Me baseline (Nov 2022). Check outcomes4me.com/empowerment2022 for updates — not live Lacuna patient data.

48/100

Median gap index

52/100

Weighted burden index

56/100

Mean high+ severity

Critical gaps (≥60)

Max gap index

Curated links

Evidence-backed links

Unweighted mean 47/100 across 12 dimensions · mean evidence coverage 15% · n=1,828 survey · max gap: Presented with clinical trial as treatment option

Timely, actionable medical records

Mean gap 44/100

44/100

3 metrics · 24 companies · 11 deals

Trusted multidisciplinary care team

Mean gap 40/100

40/100

3 metrics · 46 companies · 28 deals

Evidence-based standards presented

Mean gap 59/100

59/100

2 metrics · 38 companies · 24 deals

Health and life goals integrated

Mean gap 48/100

48/100

4 metrics · 37 companies · 26 deals

Care-phase mean gap index

Medical records access

44/100

Detection & diagnosis

38/100

Active treatment

52/100

Survivorship

61/100

Overall empowerment

27/100

Severity distribution (12 dimensions)

Critical (≥60)

High (40–59)

Moderate (<40)

Gap index by dimension

clinical trial offered

unaware survivorship resources

full records access

no survivorship plan

hipaa compliant institutions

uncomfortable advocating

care team accessible

oncologist listens

genetic testing not recommended

not in control

records not understandable

portal diagnosis

Priority ranking (gap × thin coverage)

Dimension	Gap index	Priority	Evidence	Coverage
Patients with full access to medical records	55/100	51	4%evidence	8%curated
Institutions fully compliant with HIPAA records requests	53/100	50	0%evidence	5%curated
Did not feel comfortable advocating to care team	50/100	47	6%evidence	6%curated
Presented with clinical trial as treatment option	80/100	46	42%evidence	42%curated
Not aware of survivorship resources	67/100	42	38%evidence	38%curated

Top gaps by index (portfolio detail)

Gap dimension	Gap index	Portfolio affinity	Deals
Presented with clinical trial as treatment option Cited: 1 in 5 · Cited survey (HLTH 2022)	80/100 critical	b.well (Affinity (sector)) Biotheranostics (Affinity (sector)) E-Lovu Health (Affinity (sector)) +19 more	14n=19 addressable42% curated42% evidence58% heuristic
Not aware of survivorship resources Cited: 2 in 3 · Cited survey (HLTH 2022)	67/100 critical	b.well (Affinity (sector)) Biotheranostics (Curated analyst mapping · Company / product site)↗ E-Lovu Health (Affinity (sector)) +12 more	9n=13 addressable38% curated38% evidence62% heuristic
Patients with full access to medical records Cited: 45% · Cited survey (HLTH 2022)	55/100 high	Alere (Affinity (sector)) AOA Dx (Affinity (sector)) b.well (Curated analyst mapping) +21 more	11n=24 addressable8% curated4% evidence92% heuristic
No survivorship care plan after active treatment Cited: 54% · Cited survey (HLTH 2022)	54/100 high	b.well (Affinity (sector)) Biotheranostics (Curated analyst mapping · Clinical trial / publication)↗ E-Lovu Health (Affinity (sector)) +16 more	13n=19 addressable63% curated58% evidence37% heuristic
Institutions fully compliant with HIPAA records requests Cited: 47% · Cited survey (HLTH 2022)	53/100 high	Alere (Affinity (sector)) AOA Dx (Affinity (sector)) b.well (Curated analyst mapping) +19 more	11n=22 addressable5% curated0% evidence95% heuristic

All 12 dimensions

Patients with full access to medical records Cited: 45% · Cited survey (HLTH 2022)	55/100 high	Alere (Affinity (sector)) AOA Dx (Affinity (sector)) b.well (Curated analyst mapping) +21 more	11n=24 addressable8% curated4% evidence92% heuristic
Institutions fully compliant with HIPAA records requests Cited: 47% · Cited survey (HLTH 2022)	53/100 high	Alere (Affinity (sector)) AOA Dx (Affinity (sector)) b.well (Curated analyst mapping) +19 more	11n=22 addressable5% curated0% evidence95% heuristic
Cannot make sense of medical records Cited: 1 in 4 · Cited survey (HLTH 2022)	25/100 moderate	Alere (Affinity (sector)) AOA Dx (Affinity (sector)) b.well (Affinity (sector)) +19 more	11n=22 addressable5% curated0% evidence95% heuristic
Learned cancer diagnosis via portal before care team Cited: 1 in 4 · Cited survey (HLTH 2022)	25/100 moderate	Alere (Affinity (sector)) AOA Dx (Affinity (sector)) b.well (Affinity (sector)) +27 more	18n=29 addressable3% curated0% evidence97% heuristic
Did not feel comfortable advocating to care team Cited: 1 in 2 · Cited survey (HLTH 2022)	50/100 high	b.well (Affinity (sector)) Biotheranostics (Affinity (sector)) Calm (Affinity (sector)) +15 more	8n=17 addressable6% curated6% evidence94% heuristic
Care team accessible to answer questions Cited: ~55% · Cited survey (HLTH 2022)	45/100 high	Alloy (Affinity (keyword)) b.well (Affinity (sector)) Biotheranostics (Affinity (sector)) +24 more	17n=19 addressable11% curated5% evidence89% heuristic
Oncologist listens; wishes reflected in treatment plan Cited: 56% · Cited survey (HLTH 2022)	44/100 high	Apostrophe (Affinity (keyword)) b.well (Affinity (sector)) Biotheranostics (Affinity (sector)) +18 more	15n=19 addressable11% curated11% evidence89% heuristic
Not recommended genetic testing (NCCN: almost all should) Cited: 37% · Cited survey (HLTH 2022)	37/100 moderate	Alere (Affinity (sector)) AOA Dx (Affinity (sector)) Biotheranostics (Curated analyst mapping · Company / product site)↗ +27 more	24n=29 addressable34% curated14% evidence66% heuristic
Presented with clinical trial as treatment option Cited: 1 in 5 · Cited survey (HLTH 2022)	80/100 critical	b.well (Affinity (sector)) Biotheranostics (Affinity (sector)) E-Lovu Health (Affinity (sector)) +19 more	14n=19 addressable42% curated42% evidence58% heuristic
No survivorship care plan after active treatment Cited: 54% · Cited survey (HLTH 2022)	54/100 high	b.well (Affinity (sector)) Biotheranostics (Curated analyst mapping · Clinical trial / publication)↗ E-Lovu Health (Affinity (sector)) +16 more	13n=19 addressable63% curated58% evidence37% heuristic
Not aware of survivorship resources Cited: 2 in 3 · Cited survey (HLTH 2022)	67/100 critical	b.well (Affinity (sector)) Biotheranostics (Curated analyst mapping · Company / product site)↗ E-Lovu Health (Affinity (sector)) +12 more	9n=13 addressable38% curated38% evidence62% heuristic
Do not feel in control of care decisions Cited: 27% · Cited survey (HLTH 2022)	27/100 moderate	Alere (Affinity (sector)) AOA Dx (Affinity (sector)) b.well (Affinity (sector)) +32 more	24n=35 addressable0% curated0% evidence100% heuristic

HLTH Foundation / Outcomes4Me 2022 breast cancer empowerment baseline crosswalked to Lacuna's verified M&A sample using curated analyst mappings (preferred), sector overlap, and description keyword affinity. Gap indices are cited static rates — not live patient outcomes, clinical benchmarks, or investment advice.

Sources

HLTH Foundation — State of Patient Empowerment (PDF) — Outcomes4Me & HLTH Foundation. The State of Patient Empowerment Report, 2022 Edition. Nov 14, 2022. Partnership with Boston Consulting Group and IQVIA.
Outcomes4Me — empowerment2022 — Full methodology and interactive results. outcomes4me.com/empowerment2022

Gap analyst (LLM)

Grounded only in the empowerment snapshot JSON. Deterministic summary when inference is not configured.

Genetic Markers & Health Equity

Maternal mortality, PCOS, hereditary breast cancer, sickle cell, lupus, and Lynch syndrome — with disparities that disproportionately affect Black women in the verified portfolio.

Health equity context

Public-health framing with cited static epidemiology, mapped to companies in the verified sample. Filter, expand records, or export the overlap table.

Dataset 2026-09-20

What you can do here

Filter by focus area, sector, or company; expand a row for sources and deal provenance.
Epidemiology numbers are static citations (OAIS reference list), not a live CDC feed.
Dual-metric ROI scoring lives under Impact Assessment.

Focus areaSectorCompanySearch company nameOnly areas with sample companies

Showing 6 of 6 focus areas · 158 company rows

Focus areas

Sample cos. in related sectors

Verified deals (those targets)

Areas with ≥1 sample company

Maternal mortality remains substantially higher for Black women in the United States. Remote monitoring, access, quality-improvement and early-warning approaches are relevant diligence themes, but clinical benefit must be evaluated separately from the disparity statistic.

Disparity / prevalence (static)

2024 maternal mortality: Black women 44.8 vs White women 14.2 deaths per 100,000 live births (~3.2×). Separately, CDC MMRC review of 2017–2019 pregnancy-related deaths found >80% preventable.

Addressable population: 0.85M US women (0.7–1M, 2026)

Source: CDC/NCHS Maternal Mortality Rates in the United States, 2024 (published Mar 2026); CDC Maternal Mortality Review Committees, 2017–2019 preventability analysis

Verified portfolio overlap (Maternal Health, Diagnostics, Wearables) · 21 companies

Alydia HealthMaternal Health · Acquired by Organon (2021)
Medical device company focused on preventing maternal morbidity from postpartum hemorrhage (Jada System)
Verified deal: acquired by Organon (via Merck spinoff) (2021-03-30) — Up to $240M total ($215M upfront cash + $25M contingent milestone); Organon press release Mar 30, 2021
Sources (4)
- Organon.com - press release (Mar 30, 2021)
- Business Wire - Merck acquisition on behalf of Organon spinoff
- Crunchbase - crunchbase.com/organization/alydia-health
- Organon press release - acquisition announcement, 2021
View network graph Full dataset JSON
IgenomixDiagnostics · Acquired by Vitrolife (2021)
Global leader in reproductive genetic testing services for IVF clinics — preimplantation genetic testing across 26 countries
Verified deal: acquired by Vitrolife (2021-07-08) — Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
Sources (3)
- Cision/Vitrolife press release (Jul 8, 2021)
- PR Newswire - acquisition completion (Nov 30, 2021)
- EQT Group - sale announcement
View network graph Full dataset JSON
SequenomDiagnostics · Acquired by LabCorp (2016)
Pioneer in non-invasive prenatal testing (NIPT) — MaterniT21 test for fetal chromosomal abnormalities, over 500K tests performed
Verified deal: acquired by LabCorp (2016-07-27) — Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
Sources (2)
- SEC EDGAR - LabCorp/Sequenom merger filing (Jul 27, 2016)
- Business Wire - acquisition announcement
View network graph Full dataset JSON
nVision MedicalDiagnostics · Acquired by Boston Scientific (2018)
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
Verified deal: acquired by Boston Scientific (2018-04-16) — $150M upfront + up to $125M in milestones over 4 years
Sources (2)
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
View network graph Full dataset JSON
CounsylDiagnostics · Acquired by Myriad Genetics (2018)
Prenatal and carrier genetic screening — Foresight carrier screen and Prequel NIPT (non-invasive prenatal testing); one of largest reproductive genetics labs in US
Verified deal: acquired by Myriad Genetics (2018-05-28) — ~$375M ($225M cash + $150M equity consideration)
Sources (2)
- Globe Newswire — Myriad Genetics press release (May 28, 2018)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Gateway GenomicsDiagnostics · Acquired by Myriad Genetics (2022)
Consumer genetic testing — SneakPeek early gender DNA test (detects baby gender at 6 weeks with 99% accuracy); 750K+ parents served, 20%+ CAGR
Verified deal: acquired by Myriad Genetics (2022-11-01) — $67.5M tuck-in acquisition (Myriad Genetics press release)
Sources (2)
- Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Invitae Reproductive HealthDiagnostics · Assets acquired by Natera (2024)
Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio
Verified deal: acquired by Natera (2024-01-22) — $10M upfront + up to $42.5M milestones (cash + litigation credits)
Sources (2)
- Business Wire — Natera press release (Jan 22, 2024)
- Natera investor relations
View network graph Full dataset JSON
Thrive Earlier DetectionDiagnostics · Acquired by Exact Sciences (2021)
Multi-cancer blood test (CancerSEEK) using cfDNA and protein biomarkers to detect multiple cancer types including breast and ovarian
Verified deal: acquired by Exact Sciences (2020-10-27) — ~$2.15B cash + stock
Sources (3)
- PR Newswire — Exact Sciences/Thrive announcement (Oct 27, 2020)
- PR Newswire — Exact Sciences completion (Jan 5, 2021)
- Milwaukee Business Journal (Jan 5, 2021)
View network graph Full dataset JSON
PreventionGeneticsDiagnostics · Acquired by Exact Sciences (2022)
CLIA-certified genetic testing laboratory — 5,000+ predefined tests for hereditary cancer (BRCA1/2, Lynch syndrome), carrier screening, and whole exome/genome sequencing
Verified deal: acquired by Exact Sciences (2022-01-09) — ~$190M (Laboratory Economics reporting)
Sources (3)
- PR Newswire — Exact Sciences press release (Jan 9, 2022)
- SEC EDGAR — Exact Sciences 8-K (Jan 10, 2022)
- Laboratory Economics — deal reporting (Jan 15, 2022)
View network graph Full dataset JSON
EUROIMMUNDiagnostics · Acquired by PerkinElmer (2017)
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
Verified deal: acquired by PerkinElmer (Revvity) (2017-06-16) — ~$1.3B cash
Sources (3)
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
View network graph Full dataset JSON
AlereDiagnostics · Acquired by Abbott (2017)
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
Verified deal: acquired by Abbott Laboratories (2016-02-01) — $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Sources (3)
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
View network graph Full dataset JSON
Gen-ProbeDiagnostics · Acquired by Hologic (2012)
Leader in molecular diagnostics including HPV/cervical cancer testing and STI screening
Verified deal: acquired by Hologic (2012-04-30) — Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
Sources (3)
- SEC EDGAR - Hologic 8-K/DEFM14A (2012)
- Hologic press release (August 1, 2012)
- Gen-Probe Incorporated SEC filings
View network graph Full dataset JSON
EvvyDiagnostics · Private (Series A)
At-home vaginal microbiome testing with metagenomic sequencing and precision treatment
No verified acquisition row for this company.
Sources (3)
- TechCrunch - $5M seed coverage (July 2021)
- Business Wire - $14M Series A announcement (September 2023)
- Fierce Healthcare - funding and STI care expansion coverage
View network graph Full dataset JSON
Testmate HealthDiagnostics · Private (Seed)
At-home rapid molecular STI test, starting with chlamydia and gonorrhea; $6M seed
No verified acquisition row for this company.
Sources (6)
- PRNewswire - $6M seed announcement (May 2024)
- Startupticker.ch - $6M seed coverage (May 2024)
- FinSMEs - seed round coverage (May 2024)
- GGBa - CHF 1.6M earlier financing coverage
- Crunchbase - crunchbase.com/organization/testmate-health
- Company website - testmatehealth.com
View network graph Full dataset JSON
Juniper GenomicsDiagnostics · Private (Seed)
Whole-genome and transcriptome embryo screening for IVF
No verified acquisition row for this company.
Sources (5)
- GenomeWeb - $4.6M seed launch coverage (June 2025)
- Femtech Insider - seed round coverage (2025)
- Future FemHealth - seed funding coverage (2025)
- Crunchbase - crunchbase.com/organization/juniper-genomics
- Company website - junipergenomics.com
View network graph Full dataset JSON
Nest CollaborativeMaternal Health · Private (Seed)
Digital lactation support platform connecting new mothers with IBCLC consultants
No verified acquisition row for this company.
Sources (3)
- Fund portfolio listing (as of 5/31/26)
- Crunchbase - crunchbase.com/organization/nest-collaborative
- Company website - nestcollaborative.com
View network graph Full dataset JSON
WillowMaternal Health · Private (Series C)
Wearable breast pump for hands-free pumping
No verified acquisition row for this company.
Sources (4)
- Fund portfolio listing (as of 5/31/26)
- Crunchbase - crunchbase.com/organization/willow-pump
- TechCrunch - breast pump startup coverage, 2021
- Company website - willowpump.com
View network graph Full dataset JSON
AOA DxDiagnostics · Private (Series B)
Glycolipid biomarker diagnostics for early ovarian cancer detection
No verified acquisition row for this company.
Sources (3)
- Endpoints News - $17M Series B; $24M total raised (October 2023)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - aoadx.com
View network graph Full dataset JSON
Eli HealthDiagnostics · Private
At-home saliva hormone monitoring with real-time insights
No verified acquisition row for this company.
Sources (3)
- Eli Health - total capital raised $20M (June 2025)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - eli.health
View network graph Full dataset JSON
NovocuffMaternal Health · Private (Series A)
Cervical cerclage device to reduce risk of preterm birth
No verified acquisition row for this company.
Sources (3)
- Business Wire - $26M Series A + $2M seed (July 2024)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - novocuff.com
View network graph Full dataset JSON
Raydiant OximetryMaternal Health · Private (Series A)
Non-invasive fetal oxygenation monitor for labor and delivery
No verified acquisition row for this company.
Sources (3)
- GlobeNewswire - $7.5M Series A extension (June 2024)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - raydiantoximetry.com
View network graph Full dataset JSON

Polygenic and rare-variant signals (DENND1A, FSHR, LHCGR) are studied in PCOS susceptibility and may be relevant to diagnostics and reproductive-health research; gene association is not itself clinical utility.

Disparity / prevalence (static)

CDC describes PCOS as affecting as many as 5 million US women; prevalence estimates vary by diagnostic criteria and population.

Addressable population: 5M US women (4–6.5M, 2026)

Source: CDC, Diabetes and Polycystic Ovary Syndrome (PCOS), May 2024; WHO PCOS fact sheet for global prevalence context

Verified portfolio overlap (Diagnostics, Reproductive Health, Fertility) · 35 companies

ORIGIO a/sFertility · Acquired by CooperSurgical (2012)
Global IVF medical device company — culture media, micro-tools, and labware for fertility treatment
Verified deal: acquired by CooperSurgical (CooperCompanies) (2012-06-04) — ~NOK 1,159M enterprise value (~$147M net of cash acquired)
Sources (2)
- SEC EDGAR - CooperCompanies 10-K (FY2012, acquisition details)
- Oslo Stock Exchange - ORIGIO tender offer (Jun 2012)
View network graph Full dataset JSON
Generate Life SciencesReproductive Health · Acquired by CooperSurgical (2022)
Donor egg and sperm for fertility, cryopreservation services, and newborn stem cell storage (cord blood and tissue)
Verified deal: acquired by CooperSurgical (CooperCompanies) (2021-11-10) — ~$1.6B (CooperCompanies press release)
Sources (2)
- CooperCompanies investor relations - press release (Nov 10, 2021)
- Globe Newswire - acquisition announcement
View network graph Full dataset JSON
Cook Medical Reproductive HealthFertility · Acquired by CooperSurgical (2022)
Reproductive health business unit of Cook Medical — IVF catheters, embryo transfer devices, and assisted reproduction products
Verified deal: acquired by CooperSurgical (CooperCompanies) (2022-02-07) — Terms not publicly disclosed
Sources (4)
- CooperCompanies investor relations - press release (Feb 7, 2022)
- Cook Medical company website
- Fierce Healthcare - Cook Medical divestiture to CooperSurgical, 2022
- Cooper Companies 10-K filing, SEC EDGAR - coopercompanies.com/investors
View network graph Full dataset JSON
ZyMōt FertilityFertility · Acquired by CooperSurgical (2024)
First-of-its-kind sperm separation device using microfluidic technology for IVF
Verified deal: acquired by CooperSurgical (2024-06-10) — Terms not publicly disclosed
Sources (5)
- CooperSurgical press release (Jun 10, 2024)
- DxNow/ZyMōt company information
- Crunchbase - crunchbase.com/organization/zymot-fertility
- CooperSurgical press release - acquisition announcement, 2024
- Company website - zymotfertility.com
View network graph Full dataset JSON
Forendo PharmaReproductive Health · Acquired by Organon (2021)
Clinical-stage drug development for endometriosis and PCOS — first-in-class HSD17B1 inhibitor (FOR-6219)
Verified deal: acquired by Organon (2021-11-11) — $75M upfront + up to $270M development milestones + $600M commercial milestones (total potential ~$954M)
Sources (2)
- Organon.com - press release (Nov 11, 2021)
- Business Wire - acquisition completion (Dec 13, 2021)
View network graph Full dataset JSON
IgenomixDiagnostics · Acquired by Vitrolife (2021)
Global leader in reproductive genetic testing services for IVF clinics — preimplantation genetic testing across 26 countries
Verified deal: acquired by Vitrolife (2021-07-08) — Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
Sources (3)
- Cision/Vitrolife press release (Jul 8, 2021)
- PR Newswire - acquisition completion (Nov 30, 2021)
- EQT Group - sale announcement
View network graph Full dataset JSON
CelmatixFertility · Acquired by Gedeon Richter (2026)
Women's health biotech — oral FSH receptor agonist for fertility, JNK inhibitor for endometriosis, and AMH antibodies for ovarian aging
Verified deal: acquired by Gedeon Richter (2026-03-03) — Upfront payment + development milestones (terms not fully disclosed)
Sources (5)
- Gedeon Richter press release (Mar 3, 2026)
- Budapest Stock Exchange filing
- Crunchbase - crunchbase.com/organization/celmatix
- Gedeon Richter press release - acquisition announcement, 2026
- Company website - celmatix.com
View network graph Full dataset JSON
SequenomDiagnostics · Acquired by LabCorp (2016)
Pioneer in non-invasive prenatal testing (NIPT) — MaterniT21 test for fetal chromosomal abnormalities, over 500K tests performed
Verified deal: acquired by LabCorp (2016-07-27) — Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
Sources (2)
- SEC EDGAR - LabCorp/Sequenom merger filing (Jul 27, 2016)
- Business Wire - acquisition announcement
View network graph Full dataset JSON
nVision MedicalDiagnostics · Acquired by Boston Scientific (2018)
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
Verified deal: acquired by Boston Scientific (2018-04-16) — $150M upfront + up to $125M in milestones over 4 years
Sources (2)
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
View network graph Full dataset JSON
Hamilton ThorneFertility · Acquired by Astorg (2024)
Precision laser devices, advanced imaging systems, consumables and software for assisted reproductive technology (ART) and IVF labs — products used in 115+ countries
Verified deal: acquired by Astorg (2024-07-22) — C$10.50/share take-private; ~$282M equity value (Weil/Astorg announcement)
Sources (3)
- Business Wire — Astorg press release (Dec 2, 2024)
- Mergr M&A summary ($388M total)
- Weil Gotshal advisory announcement ($282M)
View network graph Full dataset JSON
eFertility (STB Zorg)Fertility · Acquired by Vitrolife (2024)
IVF clinic management software — eWitness (step-by-step tracking/tracing) and eBase (specialized EMR compatible with hospital systems); leading presence in Netherlands, expanding across Europe
Verified deal: acquired by Vitrolife (2024-05-02) — Terms not publicly disclosed
Sources (4)
- Cision — Vitrolife press release (May 22, 2024)
- Vitrolife investor relations
- Vitrolife press release - eFertility acquisition, 2024
- Company website - stbzorg.nl
View network graph Full dataset JSON
Myovant SciencesReproductive Health · Acquired by Sumitovant Biopharma (2023)
Women's health and oncology pharma — Myfembree (relugolix combo for uterine fibroids and endometriosis pain) and Orgovyx (prostate cancer); first oral GnRH antagonist combination approved for women's health
Verified deal: acquired by Sumitovant Biopharma (Sumitomo Pharma) (2022-10-24) — $27/share for outstanding minority (~$1.7B); total company value ~$2.9B fully diluted; Sumitovant already owned ~52%
Sources (3)
- Sumitomo Pharma press release (Oct 24, 2022)
- PR Newswire — Sumitovant announcement (Oct 2, 2022)
- Business Wire — completion announcement (Mar 10, 2023)
View network graph Full dataset JSON
CounsylDiagnostics · Acquired by Myriad Genetics (2018)
Prenatal and carrier genetic screening — Foresight carrier screen and Prequel NIPT (non-invasive prenatal testing); one of largest reproductive genetics labs in US
Verified deal: acquired by Myriad Genetics (2018-05-28) — ~$375M ($225M cash + $150M equity consideration)
Sources (2)
- Globe Newswire — Myriad Genetics press release (May 28, 2018)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Gateway GenomicsDiagnostics · Acquired by Myriad Genetics (2022)
Consumer genetic testing — SneakPeek early gender DNA test (detects baby gender at 6 weeks with 99% accuracy); 750K+ parents served, 20%+ CAGR
Verified deal: acquired by Myriad Genetics (2022-11-01) — $67.5M tuck-in acquisition (Myriad Genetics press release)
Sources (2)
- Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Invitae Reproductive HealthDiagnostics · Assets acquired by Natera (2024)
Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio
Verified deal: acquired by Natera (2024-01-22) — $10M upfront + up to $42.5M milestones (cash + litigation credits)
Sources (2)
- Business Wire — Natera press release (Jan 22, 2024)
- Natera investor relations
View network graph Full dataset JSON
TherapeuticsMDReproductive Health · Products licensed to Mayne Pharma (2023)
Women's health hormone therapy — BIJUVA (bio-identical estradiol/progesterone for menopause), ANNOVERA (contraceptive vaginal ring), IMVEXXY (estradiol vaginal inserts); $153M total consideration
Verified deal: acquired by Mayne Pharma (2022-12-30) — $140M upfront license + $13.1M working capital + up to $30M milestones + 20-year royalties
Sources (2)
- Business Wire — TherapeuticsMD press release (Jan 3, 2023)
- SEC EDGAR — TherapeuticsMD 8-K (Dec 30, 2022)
View network graph Full dataset JSON
Thrive Earlier DetectionDiagnostics · Acquired by Exact Sciences (2021)
Multi-cancer blood test (CancerSEEK) using cfDNA and protein biomarkers to detect multiple cancer types including breast and ovarian
Verified deal: acquired by Exact Sciences (2020-10-27) — ~$2.15B cash + stock
Sources (3)
- PR Newswire — Exact Sciences/Thrive announcement (Oct 27, 2020)
- PR Newswire — Exact Sciences completion (Jan 5, 2021)
- Milwaukee Business Journal (Jan 5, 2021)
View network graph Full dataset JSON
PreventionGeneticsDiagnostics · Acquired by Exact Sciences (2022)
CLIA-certified genetic testing laboratory — 5,000+ predefined tests for hereditary cancer (BRCA1/2, Lynch syndrome), carrier screening, and whole exome/genome sequencing
Verified deal: acquired by Exact Sciences (2022-01-09) — ~$190M (Laboratory Economics reporting)
Sources (3)
- PR Newswire — Exact Sciences press release (Jan 9, 2022)
- SEC EDGAR — Exact Sciences 8-K (Jan 10, 2022)
- Laboratory Economics — deal reporting (Jan 15, 2022)
View network graph Full dataset JSON
EUROIMMUNDiagnostics · Acquired by PerkinElmer (2017)
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
Verified deal: acquired by PerkinElmer (Revvity) (2017-06-16) — ~$1.3B cash
Sources (3)
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
View network graph Full dataset JSON
AlereDiagnostics · Acquired by Abbott (2017)
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
Verified deal: acquired by Abbott Laboratories (2016-02-01) — $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Sources (3)
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
View network graph Full dataset JSON
Gen-ProbeDiagnostics · Acquired by Hologic (2012)
Leader in molecular diagnostics including HPV/cervical cancer testing and STI screening
Verified deal: acquired by Hologic (2012-04-30) — Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
Sources (3)
- SEC EDGAR - Hologic 8-K/DEFM14A (2012)
- Hologic press release (August 1, 2012)
- Gen-Probe Incorporated SEC filings
View network graph Full dataset JSON
IVI-RMA GlobalFertility · Acquired by KKR (2023)
World's largest fertility clinic network; 75+ clinics and 28 labs in 9 countries; formed from 2017 merger of Spain's IVI and US-based RMANJ
Verified deal: acquired by KKR (2022-03-01) — ~€3B ($3.25B) for 80% stake; world's largest fertility clinic acquisition; founders retained 20%
Sources (3)
- Axios Pro (April 13, 2022) - deal announcement
- Fertility Bridge (January 26, 2023) - deal close confirmation
- Spanish CNMC regulatory approval (December 21, 2022)
View network graph Full dataset JSON
Indira IVFFertility · Majority stake acquired by BPEA EQT (2023)
India's largest chain of fertility clinics; 115+ centers; 125,000+ successful pregnancies; top 5 globally by annual IVF cycles
Verified deal: acquired by BPEA EQT (2023-07-28) — Rs 5,400 crore (~$657M) for 60% majority stake; enterprise valued at ~$1.1B (Times of India)
Sources (3)
- EQT Group press release (July 28, 2023)
- Times of India (July 29, 2023)
- Economic Times (July 29, 2023)
View network graph Full dataset JSON
Eugin Group (North American operations)Fertility · Acquired by IVI-RMA/KKR (2024)
Global fertility network including Boston IVF and TRIO (Toronto); 13 labs and 32 satellite offices in North America
Verified deal: acquired by KKR (via IVI-RMA) (2023-11-01) — Part of KKR/GED Capital €494M (~$534M) acquisition of Eugin from Fresenius; this covers Boston IVF and TRIO
Sources (3)
- Business Wire - IVI RMA completion announcement (January 31, 2024)
- PitchBook (November 2023) - deal reporting
- Fresenius SE press release (divestiture)
View network graph Full dataset JSON
EvvyDiagnostics · Private (Series A)
At-home vaginal microbiome testing with metagenomic sequencing and precision treatment
No verified acquisition row for this company.
Sources (3)
- TechCrunch - $5M seed coverage (July 2021)
- Business Wire - $14M Series A announcement (September 2023)
- Fierce Healthcare - funding and STI care expansion coverage
View network graph Full dataset JSON
Béa FertilityFertility · Private (Seed)
At-home intracervical insemination (ICI) fertility treatment kits
No verified acquisition row for this company.
Sources (6)
- EU-Startups - €2.9M raise, €3.8M total coverage (July 2023)
- UKTN - £800K pre-launch raise coverage (April 2021)
- Startups Magazine - £2.5M raise coverage (2023)
- Crunchbase - crunchbase.com/organization/bea-fertility
- TechCrunch - at-home insemination kit coverage, 2022
- Company website - beafertility.com
View network graph Full dataset JSON
Granata BioFertility · Private (Series A)
In-licenses and commercializes fertility medications for North America
No verified acquisition row for this company.
Sources (2)
- PR Newswire - $14M Series A led by GV (January 2024)
- PR Newswire - $15M Series A+, total funding over $30M (January 2025)
View network graph Full dataset JSON
Gesynta PharmaReproductive Health · Private (Series B)
Clinical-stage pharma developing vipoglanstat, a non-hormonal endometriosis treatment; SEK 347M Series B
No verified acquisition row for this company.
Sources (3)
- ArcticStartup - €26.5M Series B coverage
- Femtech Insider - Series B second closing, SEK 347M total round
- Company website - gesynta.se history page (founded 2017, Karolinska spinout)
View network graph Full dataset JSON
Testmate HealthDiagnostics · Private (Seed)
At-home rapid molecular STI test, starting with chlamydia and gonorrhea; $6M seed
No verified acquisition row for this company.
Sources (6)
- PRNewswire - $6M seed announcement (May 2024)
- Startupticker.ch - $6M seed coverage (May 2024)
- FinSMEs - seed round coverage (May 2024)
- GGBa - CHF 1.6M earlier financing coverage
- Crunchbase - crunchbase.com/organization/testmate-health
- Company website - testmatehealth.com
View network graph Full dataset JSON
Juniper GenomicsDiagnostics · Private (Seed)
Whole-genome and transcriptome embryo screening for IVF
No verified acquisition row for this company.
Sources (5)
- GenomeWeb - $4.6M seed launch coverage (June 2025)
- Femtech Insider - seed round coverage (2025)
- Future FemHealth - seed funding coverage (2025)
- Crunchbase - crunchbase.com/organization/juniper-genomics
- Company website - junipergenomics.com
View network graph Full dataset JSON
AOA DxDiagnostics · Private (Series B)
Glycolipid biomarker diagnostics for early ovarian cancer detection
No verified acquisition row for this company.
Sources (3)
- Endpoints News - $17M Series B; $24M total raised (October 2023)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - aoadx.com
View network graph Full dataset JSON
Cadence OTCReproductive Health · Private
Over-the-counter birth control pill developer for accessible contraception
No verified acquisition row for this company.
Sources (3)
- Business Wire - more than $35M raised (March 2024)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - cadenceotc.com
View network graph Full dataset JSON
Eli HealthDiagnostics · Private
At-home saliva hormone monitoring with real-time insights
No verified acquisition row for this company.
Sources (3)
- Eli Health - total capital raised $20M (June 2025)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - eli.health
View network graph Full dataset JSON
Ocon MedReproductive Health · Private
Intrauterine drug-delivery platform for women's health conditions
No verified acquisition row for this company.
Sources (3)
- PRNewswire - $10M funding round (June 2024)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - oconmed.com
View network graph Full dataset JSON
Vitra LabsFertility · Private
IVF laboratory tools and embryo culture technology
No verified acquisition row for this company.
Sources (3)
- SEC Form D - November 2024 offering
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - vitra.bio
View network graph Full dataset JSON

BRCA1/2, PALB2, and CHEK2 pathogenic variants are established hereditary-cancer risk markers. Genomic profiling is relevant to precision-oncology diligence, while access and outcome disparities should remain separately sourced claims.

Disparity / prevalence (static)

Black women have 38% higher breast-cancer mortality than White women despite lower incidence (ACS Breast Cancer Statistics 2024 / Black cancer statistics 2025).

Addressable population: 4.1M US women (3.8–4.4M, 2025)

Source: American Cancer Society, Breast Cancer Facts & Figures 2024–2025; Cancer Statistics for African American/Black People, 2025

HLTH 2022 breast cancer baseline (n=1,828)

Report: Presented with clinical trial as treatment option (index 80). Weighted burden 52/100 · 2 critical gaps. Crosswalk: 48 curated · 35 evidence-backed.

Gap × portfolio matrix →

Verified portfolio overlap (Breast Health, Precision Medicine, Diagnostics) · 29 companies

BiotheranosticsBreast Health · Acquired by Hologic (2021)
Molecular diagnostic tests for breast and metastatic cancers (Breast Cancer Index, CancerTYPE ID)
Verified deal: acquired by Hologic (2021-01-05) — ~$230M subject to working capital adjustments
Sources (2)
- Hologic investor relations - press release (Jan 5, 2021)
- Business Wire - acquisition completion (Feb 22, 2021)
View network graph Full dataset JSON
EndomagneticsBreast Health · Acquired by Hologic (2024)
Magnetic marker and localization technology for breast cancer surgery (Magseed, Sentimag)
Verified deal: acquired by Hologic (2024-05-20) — ~$310M (Nasdaq/Hologic press release)
Sources (2)
- Nasdaq press release - Hologic acquisition (Jul 25, 2024)
- Endomagnetics company website - endomagnetics.com
View network graph Full dataset JSON
IgenomixDiagnostics · Acquired by Vitrolife (2021)
Global leader in reproductive genetic testing services for IVF clinics — preimplantation genetic testing across 26 countries
Verified deal: acquired by Vitrolife (2021-07-08) — Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
Sources (3)
- Cision/Vitrolife press release (Jul 8, 2021)
- PR Newswire - acquisition completion (Nov 30, 2021)
- EQT Group - sale announcement
View network graph Full dataset JSON
SequenomDiagnostics · Acquired by LabCorp (2016)
Pioneer in non-invasive prenatal testing (NIPT) — MaterniT21 test for fetal chromosomal abnormalities, over 500K tests performed
Verified deal: acquired by LabCorp (2016-07-27) — Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
Sources (2)
- SEC EDGAR - LabCorp/Sequenom merger filing (Jul 27, 2016)
- Business Wire - acquisition announcement
View network graph Full dataset JSON
Genomic HealthPrecision Medicine · Acquired by Exact Sciences (2019)
Oncotype DX genomic tests for breast, colon, and prostate cancer — used to guide chemotherapy decisions for early-stage breast cancer
Verified deal: acquired by Exact Sciences (2019-07-29) — ~$2.8B total consideration
Sources (2)
- Exact Sciences newsroom - press release (Jul 29, 2019)
- SEC EDGAR - merger proxy filing
View network graph Full dataset JSON
Foundation MedicinePrecision Medicine · Acquired by Roche (2018)
Comprehensive genomic profiling (CGP) for cancer — FoundationOne tests guide precision treatment including breast and ovarian cancer
Verified deal: acquired by Roche (2018-06-19) — $137/share for remaining shares (~$2.4B); total company value ~$5.3B fully diluted
Sources (5)
- Roche media release (Jun 19, 2018)
- Fierce Biotech - deal coverage
- SEC EDGAR - 10-K filing (CIK 0001573773, ticker FMI)
- Roche 8-K filing - acquisition announcement, 2018
- Company website - foundationmedicine.com
View network graph Full dataset JSON
Flatiron HealthPrecision Medicine · Acquired by Roche (2018)
Oncology-specific EHR and real-world evidence platform — 265+ community cancer clinics, data includes breast and ovarian cancer outcomes
Verified deal: acquired by Roche (2018-01-08) — ~$1.9B fully diluted, subject to adjustments
Sources (5)
- Roche media release (Apr 6, 2018)
- Flatiron Health company website
- Crunchbase - crunchbase.com/organization/flatiron-health
- Roche press release - acquisition announcement, 2018
- Company website - flatiron.com
View network graph Full dataset JSON
Focal TherapeuticsBreast Health · Acquired by Hologic (2018)
BioZorb implantable 3D marker for breast conserving surgery (lumpectomy) — marks tumor excision site for monitoring and treatment planning
Verified deal: acquired by Hologic (2018-09-26) — ~$125M cash (SEC filing shows $120.1M final purchase price)
Sources (2)
- Hologic investor relations press release (Sep 26, 2018)
- SEC EDGAR — Hologic 10-K FY2019 (purchase price $120.1M)
View network graph Full dataset JSON
nVision MedicalDiagnostics · Acquired by Boston Scientific (2018)
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
Verified deal: acquired by Boston Scientific (2018-04-16) — $150M upfront + up to $125M in milestones over 4 years
Sources (2)
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
View network graph Full dataset JSON
GRAILPrecision Medicine · Acquired by Illumina (2021)
Multi-cancer early detection via blood-based screening (Galleri test) — uses cfDNA and machine learning to detect 50+ cancer types including breast and ovarian; spun out of Illumina
Verified deal: acquired by Illumina (2020-09-21) — $8B cash + stock; GRAIL stockholders also receive tiered revenue-based payments
Sources (3)
- Illumina press release (Sep 21, 2020)
- SEC EDGAR — Illumina merger filing
- GRAIL press release (Aug 18, 2021 — completion)
View network graph Full dataset JSON
CounsylDiagnostics · Acquired by Myriad Genetics (2018)
Prenatal and carrier genetic screening — Foresight carrier screen and Prequel NIPT (non-invasive prenatal testing); one of largest reproductive genetics labs in US
Verified deal: acquired by Myriad Genetics (2018-05-28) — ~$375M ($225M cash + $150M equity consideration)
Sources (2)
- Globe Newswire — Myriad Genetics press release (May 28, 2018)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Gateway GenomicsDiagnostics · Acquired by Myriad Genetics (2022)
Consumer genetic testing — SneakPeek early gender DNA test (detects baby gender at 6 weeks with 99% accuracy); 750K+ parents served, 20%+ CAGR
Verified deal: acquired by Myriad Genetics (2022-11-01) — $67.5M tuck-in acquisition (Myriad Genetics press release)
Sources (2)
- Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Invitae Reproductive HealthDiagnostics · Assets acquired by Natera (2024)
Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio
Verified deal: acquired by Natera (2024-01-22) — $10M upfront + up to $42.5M milestones (cash + litigation credits)
Sources (2)
- Business Wire — Natera press release (Jan 22, 2024)
- Natera investor relations
View network graph Full dataset JSON
SeagenPrecision Medicine · Acquired by Pfizer (2023)
Antibody-drug conjugate (ADC) oncology platform — Adcetris, Padcev, Tukysa (HER2+ breast cancer), and Tivdak (cervical cancer)
Verified deal: acquired by Pfizer (2023-03-13) — $229/share, ~$43B enterprise value
Sources (3)
- SEC EDGAR — Pfizer 8-K (Mar 13, 2023)
- Business Wire — Pfizer/Seagen merger announcement (Mar 13, 2023)
- SEC EDGAR — Pfizer 8-K completion (Dec 14, 2023)
View network graph Full dataset JSON
Varian Medical SystemsPrecision Medicine · Acquired by Siemens Healthineers (2021)
Radiation oncology and cancer treatment systems — linear accelerators, brachytherapy, and treatment planning software for breast, cervical, and other cancers
Verified deal: acquired by Siemens Healthineers (2020-08-02) — $177.50/share, ~$16.4B all-cash
Sources (3)
- Siemens Healthineers press release (Aug 2, 2020)
- PR Newswire — Varian merger announcement (Aug 2, 2020)
- SEC EDGAR — Varian DFAN14A (Aug 2020)
View network graph Full dataset JSON
ImmunomedicsBreast Health · Acquired by Gilead Sciences (2020)
Developer of Trodelvy (sacituzumab govitecan), first-in-class Trop-2 ADC for metastatic triple-negative breast cancer (mTNBC)
Verified deal: acquired by Gilead Sciences (2020-09-13) — $88/share, ~$21B
Sources (3)
- Business Wire — Gilead/Immunomedics announcement (Sep 13, 2020)
- Gilead Sciences press release (Sep 13, 2020)
- SEC EDGAR — Immunomedics merger filing
View network graph Full dataset JSON
Thrive Earlier DetectionDiagnostics · Acquired by Exact Sciences (2021)
Multi-cancer blood test (CancerSEEK) using cfDNA and protein biomarkers to detect multiple cancer types including breast and ovarian
Verified deal: acquired by Exact Sciences (2020-10-27) — ~$2.15B cash + stock
Sources (3)
- PR Newswire — Exact Sciences/Thrive announcement (Oct 27, 2020)
- PR Newswire — Exact Sciences completion (Jan 5, 2021)
- Milwaukee Business Journal (Jan 5, 2021)
View network graph Full dataset JSON
PreventionGeneticsDiagnostics · Acquired by Exact Sciences (2022)
CLIA-certified genetic testing laboratory — 5,000+ predefined tests for hereditary cancer (BRCA1/2, Lynch syndrome), carrier screening, and whole exome/genome sequencing
Verified deal: acquired by Exact Sciences (2022-01-09) — ~$190M (Laboratory Economics reporting)
Sources (3)
- PR Newswire — Exact Sciences press release (Jan 9, 2022)
- SEC EDGAR — Exact Sciences 8-K (Jan 10, 2022)
- Laboratory Economics — deal reporting (Jan 15, 2022)
View network graph Full dataset JSON
EUROIMMUNDiagnostics · Acquired by PerkinElmer (2017)
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
Verified deal: acquired by PerkinElmer (Revvity) (2017-06-16) — ~$1.3B cash
Sources (3)
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
View network graph Full dataset JSON
Faxitron BiopticsBreast Health · Acquired by Hologic (2018)
Digital specimen radiography, breast lesion localization (LOCalizer), and sentinel lymph node biopsy solutions — VisionCT first 3D breast specimen CT system
Verified deal: acquired by Hologic (2018-07-31) — ~$85M (Hologic press release)
Sources (3)
- PR Newswire — Hologic press release (Jul 31, 2018)
- BioSpace — deal coverage (Jul 31, 2018)
- Hologic investor relations — SEC 10-K FY2019
View network graph Full dataset JSON
SuperSonic ImagineBreast Health · Acquired by Hologic (2019)
ShearWave elastography and Aixplorer ultrasound platform for breast cancer diagnosis — non-invasive tissue stiffness measurement for breast lesion characterization
Verified deal: acquired by Hologic (2019-06-21) — ~$85M total (€1.50/share equity + up to $43M debt payoff)
Sources (5)
- MassDevice — Hologic/SSI announcement (Jun 21, 2019)
- AuntMinnie — Hologic acquires 46% stake (Aug 4, 2019)
- Euronext Paris — SuperSonic Imagine (EPA: SSI) tender offer
- Crunchbase - crunchbase.com/organization/supersonic-imagine
- Hologic press release - acquisition announcement, 2019
View network graph Full dataset JSON
Sividon DiagnosticsBreast Health · Acquired by Myriad Genetics (2016)
EndoPredict breast cancer prognostic test — 12-gene RNA expression assay evaluating breast cancer aggressiveness; spun out of Siemens Healthcare Diagnostics
Verified deal: acquired by Myriad Genetics (2016-05-31) — €35M upfront + up to €15M performance milestones (~$56M total potential)
Sources (3)
- Globe Newswire — Myriad Genetics press release (May 31, 2016)
- SEC EDGAR — Myriad Genetics 8-K (May 31, 2016)
- GEN News — deal coverage (May 31, 2016)
View network graph Full dataset JSON
AlereDiagnostics · Acquired by Abbott (2017)
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
Verified deal: acquired by Abbott Laboratories (2016-02-01) — $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Sources (3)
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
View network graph Full dataset JSON
Gen-ProbeDiagnostics · Acquired by Hologic (2012)
Leader in molecular diagnostics including HPV/cervical cancer testing and STI screening
Verified deal: acquired by Hologic (2012-04-30) — Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
Sources (3)
- SEC EDGAR - Hologic 8-K/DEFM14A (2012)
- Hologic press release (August 1, 2012)
- Gen-Probe Incorporated SEC filings
View network graph Full dataset JSON
EvvyDiagnostics · Private (Series A)
At-home vaginal microbiome testing with metagenomic sequencing and precision treatment
No verified acquisition row for this company.
Sources (3)
- TechCrunch - $5M seed coverage (July 2021)
- Business Wire - $14M Series A announcement (September 2023)
- Fierce Healthcare - funding and STI care expansion coverage
View network graph Full dataset JSON
Testmate HealthDiagnostics · Private (Seed)
At-home rapid molecular STI test, starting with chlamydia and gonorrhea; $6M seed
No verified acquisition row for this company.
Sources (6)
- PRNewswire - $6M seed announcement (May 2024)
- Startupticker.ch - $6M seed coverage (May 2024)
- FinSMEs - seed round coverage (May 2024)
- GGBa - CHF 1.6M earlier financing coverage
- Crunchbase - crunchbase.com/organization/testmate-health
- Company website - testmatehealth.com
View network graph Full dataset JSON
Juniper GenomicsDiagnostics · Private (Seed)
Whole-genome and transcriptome embryo screening for IVF
No verified acquisition row for this company.
Sources (5)
- GenomeWeb - $4.6M seed launch coverage (June 2025)
- Femtech Insider - seed round coverage (2025)
- Future FemHealth - seed funding coverage (2025)
- Crunchbase - crunchbase.com/organization/juniper-genomics
- Company website - junipergenomics.com
View network graph Full dataset JSON
AOA DxDiagnostics · Private (Series B)
Glycolipid biomarker diagnostics for early ovarian cancer detection
No verified acquisition row for this company.
Sources (3)
- Endpoints News - $17M Series B; $24M total raised (October 2023)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - aoadx.com
View network graph Full dataset JSON
Eli HealthDiagnostics · Private
At-home saliva hormone monitoring with real-time insights
No verified acquisition row for this company.
Sources (3)
- Eli Health - total capital raised $20M (June 2025)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - eli.health
View network graph Full dataset JSON

HBB variants cause sickle cell disease and trait, making the condition relevant to gene-therapy, diagnostics and newborn-screening diligence; population burden and therapeutic value remain separate questions.

Disparity / prevalence (static)

CDC reports SCD occurs in about 1 in 365 Black or African American births and sickle-cell trait in about 1 in 13 Black or African American babies.

Addressable population: 0.1M US women (0.09–0.12M, 2024)

Source: CDC Sickle Cell Disease data and surveillance; NHLBI sickle cell resources

Verified portfolio overlap (Diagnostics, Precision Medicine) · 22 companies

IgenomixDiagnostics · Acquired by Vitrolife (2021)
Global leader in reproductive genetic testing services for IVF clinics — preimplantation genetic testing across 26 countries
Verified deal: acquired by Vitrolife (2021-07-08) — Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
Sources (3)
- Cision/Vitrolife press release (Jul 8, 2021)
- PR Newswire - acquisition completion (Nov 30, 2021)
- EQT Group - sale announcement
View network graph Full dataset JSON
SequenomDiagnostics · Acquired by LabCorp (2016)
Pioneer in non-invasive prenatal testing (NIPT) — MaterniT21 test for fetal chromosomal abnormalities, over 500K tests performed
Verified deal: acquired by LabCorp (2016-07-27) — Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
Sources (2)
- SEC EDGAR - LabCorp/Sequenom merger filing (Jul 27, 2016)
- Business Wire - acquisition announcement
View network graph Full dataset JSON
Genomic HealthPrecision Medicine · Acquired by Exact Sciences (2019)
Oncotype DX genomic tests for breast, colon, and prostate cancer — used to guide chemotherapy decisions for early-stage breast cancer
Verified deal: acquired by Exact Sciences (2019-07-29) — ~$2.8B total consideration
Sources (2)
- Exact Sciences newsroom - press release (Jul 29, 2019)
- SEC EDGAR - merger proxy filing
View network graph Full dataset JSON
Foundation MedicinePrecision Medicine · Acquired by Roche (2018)
Comprehensive genomic profiling (CGP) for cancer — FoundationOne tests guide precision treatment including breast and ovarian cancer
Verified deal: acquired by Roche (2018-06-19) — $137/share for remaining shares (~$2.4B); total company value ~$5.3B fully diluted
Sources (5)
- Roche media release (Jun 19, 2018)
- Fierce Biotech - deal coverage
- SEC EDGAR - 10-K filing (CIK 0001573773, ticker FMI)
- Roche 8-K filing - acquisition announcement, 2018
- Company website - foundationmedicine.com
View network graph Full dataset JSON
Flatiron HealthPrecision Medicine · Acquired by Roche (2018)
Oncology-specific EHR and real-world evidence platform — 265+ community cancer clinics, data includes breast and ovarian cancer outcomes
Verified deal: acquired by Roche (2018-01-08) — ~$1.9B fully diluted, subject to adjustments
Sources (5)
- Roche media release (Apr 6, 2018)
- Flatiron Health company website
- Crunchbase - crunchbase.com/organization/flatiron-health
- Roche press release - acquisition announcement, 2018
- Company website - flatiron.com
View network graph Full dataset JSON
nVision MedicalDiagnostics · Acquired by Boston Scientific (2018)
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
Verified deal: acquired by Boston Scientific (2018-04-16) — $150M upfront + up to $125M in milestones over 4 years
Sources (2)
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
View network graph Full dataset JSON
GRAILPrecision Medicine · Acquired by Illumina (2021)
Multi-cancer early detection via blood-based screening (Galleri test) — uses cfDNA and machine learning to detect 50+ cancer types including breast and ovarian; spun out of Illumina
Verified deal: acquired by Illumina (2020-09-21) — $8B cash + stock; GRAIL stockholders also receive tiered revenue-based payments
Sources (3)
- Illumina press release (Sep 21, 2020)
- SEC EDGAR — Illumina merger filing
- GRAIL press release (Aug 18, 2021 — completion)
View network graph Full dataset JSON
CounsylDiagnostics · Acquired by Myriad Genetics (2018)
Prenatal and carrier genetic screening — Foresight carrier screen and Prequel NIPT (non-invasive prenatal testing); one of largest reproductive genetics labs in US
Verified deal: acquired by Myriad Genetics (2018-05-28) — ~$375M ($225M cash + $150M equity consideration)
Sources (2)
- Globe Newswire — Myriad Genetics press release (May 28, 2018)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Gateway GenomicsDiagnostics · Acquired by Myriad Genetics (2022)
Consumer genetic testing — SneakPeek early gender DNA test (detects baby gender at 6 weeks with 99% accuracy); 750K+ parents served, 20%+ CAGR
Verified deal: acquired by Myriad Genetics (2022-11-01) — $67.5M tuck-in acquisition (Myriad Genetics press release)
Sources (2)
- Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Invitae Reproductive HealthDiagnostics · Assets acquired by Natera (2024)
Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio
Verified deal: acquired by Natera (2024-01-22) — $10M upfront + up to $42.5M milestones (cash + litigation credits)
Sources (2)
- Business Wire — Natera press release (Jan 22, 2024)
- Natera investor relations
View network graph Full dataset JSON
SeagenPrecision Medicine · Acquired by Pfizer (2023)
Antibody-drug conjugate (ADC) oncology platform — Adcetris, Padcev, Tukysa (HER2+ breast cancer), and Tivdak (cervical cancer)
Verified deal: acquired by Pfizer (2023-03-13) — $229/share, ~$43B enterprise value
Sources (3)
- SEC EDGAR — Pfizer 8-K (Mar 13, 2023)
- Business Wire — Pfizer/Seagen merger announcement (Mar 13, 2023)
- SEC EDGAR — Pfizer 8-K completion (Dec 14, 2023)
View network graph Full dataset JSON
Varian Medical SystemsPrecision Medicine · Acquired by Siemens Healthineers (2021)
Radiation oncology and cancer treatment systems — linear accelerators, brachytherapy, and treatment planning software for breast, cervical, and other cancers
Verified deal: acquired by Siemens Healthineers (2020-08-02) — $177.50/share, ~$16.4B all-cash
Sources (3)
- Siemens Healthineers press release (Aug 2, 2020)
- PR Newswire — Varian merger announcement (Aug 2, 2020)
- SEC EDGAR — Varian DFAN14A (Aug 2020)
View network graph Full dataset JSON
Thrive Earlier DetectionDiagnostics · Acquired by Exact Sciences (2021)
Multi-cancer blood test (CancerSEEK) using cfDNA and protein biomarkers to detect multiple cancer types including breast and ovarian
Verified deal: acquired by Exact Sciences (2020-10-27) — ~$2.15B cash + stock
Sources (3)
- PR Newswire — Exact Sciences/Thrive announcement (Oct 27, 2020)
- PR Newswire — Exact Sciences completion (Jan 5, 2021)
- Milwaukee Business Journal (Jan 5, 2021)
View network graph Full dataset JSON
PreventionGeneticsDiagnostics · Acquired by Exact Sciences (2022)
CLIA-certified genetic testing laboratory — 5,000+ predefined tests for hereditary cancer (BRCA1/2, Lynch syndrome), carrier screening, and whole exome/genome sequencing
Verified deal: acquired by Exact Sciences (2022-01-09) — ~$190M (Laboratory Economics reporting)
Sources (3)
- PR Newswire — Exact Sciences press release (Jan 9, 2022)
- SEC EDGAR — Exact Sciences 8-K (Jan 10, 2022)
- Laboratory Economics — deal reporting (Jan 15, 2022)
View network graph Full dataset JSON
EUROIMMUNDiagnostics · Acquired by PerkinElmer (2017)
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
Verified deal: acquired by PerkinElmer (Revvity) (2017-06-16) — ~$1.3B cash
Sources (3)
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
View network graph Full dataset JSON
AlereDiagnostics · Acquired by Abbott (2017)
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
Verified deal: acquired by Abbott Laboratories (2016-02-01) — $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Sources (3)
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
View network graph Full dataset JSON
Gen-ProbeDiagnostics · Acquired by Hologic (2012)
Leader in molecular diagnostics including HPV/cervical cancer testing and STI screening
Verified deal: acquired by Hologic (2012-04-30) — Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
Sources (3)
- SEC EDGAR - Hologic 8-K/DEFM14A (2012)
- Hologic press release (August 1, 2012)
- Gen-Probe Incorporated SEC filings
View network graph Full dataset JSON
EvvyDiagnostics · Private (Series A)
At-home vaginal microbiome testing with metagenomic sequencing and precision treatment
No verified acquisition row for this company.
Sources (3)
- TechCrunch - $5M seed coverage (July 2021)
- Business Wire - $14M Series A announcement (September 2023)
- Fierce Healthcare - funding and STI care expansion coverage
View network graph Full dataset JSON
Testmate HealthDiagnostics · Private (Seed)
At-home rapid molecular STI test, starting with chlamydia and gonorrhea; $6M seed
No verified acquisition row for this company.
Sources (6)
- PRNewswire - $6M seed announcement (May 2024)
- Startupticker.ch - $6M seed coverage (May 2024)
- FinSMEs - seed round coverage (May 2024)
- GGBa - CHF 1.6M earlier financing coverage
- Crunchbase - crunchbase.com/organization/testmate-health
- Company website - testmatehealth.com
View network graph Full dataset JSON
Juniper GenomicsDiagnostics · Private (Seed)
Whole-genome and transcriptome embryo screening for IVF
No verified acquisition row for this company.
Sources (5)
- GenomeWeb - $4.6M seed launch coverage (June 2025)
- Femtech Insider - seed round coverage (2025)
- Future FemHealth - seed funding coverage (2025)
- Crunchbase - crunchbase.com/organization/juniper-genomics
- Company website - junipergenomics.com
View network graph Full dataset JSON
AOA DxDiagnostics · Private (Series B)
Glycolipid biomarker diagnostics for early ovarian cancer detection
No verified acquisition row for this company.
Sources (3)
- Endpoints News - $17M Series B; $24M total raised (October 2023)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - aoadx.com
View network graph Full dataset JSON
Eli HealthDiagnostics · Private
At-home saliva hormone monitoring with real-time insights
No verified acquisition row for this company.
Sources (3)
- Eli Health - total capital raised $20M (June 2025)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - eli.health
View network graph Full dataset JSON

HLA and interferon-pathway variants including STAT4 and IRF5 contribute to lupus susceptibility research. Genetic association should not be presented as a stand-alone diagnostic or investment moat.

Disparity / prevalence (static)

Lupus Foundation of America reports earlier disease, greater complications and higher mortality among several racial and ethnic minority groups; Black women are disproportionately affected.

Addressable population: 0.34M US women (0.16–0.5M, 2024)

Source: Lupus Foundation of America, Lupus Facts and Statistics and Health Disparities in Lupus

Verified portfolio overlap (Diagnostics, Precision Medicine) · 22 companies

IgenomixDiagnostics · Acquired by Vitrolife (2021)
Global leader in reproductive genetic testing services for IVF clinics — preimplantation genetic testing across 26 countries
Verified deal: acquired by Vitrolife (2021-07-08) — Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
Sources (3)
- Cision/Vitrolife press release (Jul 8, 2021)
- PR Newswire - acquisition completion (Nov 30, 2021)
- EQT Group - sale announcement
View network graph Full dataset JSON
SequenomDiagnostics · Acquired by LabCorp (2016)
Pioneer in non-invasive prenatal testing (NIPT) — MaterniT21 test for fetal chromosomal abnormalities, over 500K tests performed
Verified deal: acquired by LabCorp (2016-07-27) — Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
Sources (2)
- SEC EDGAR - LabCorp/Sequenom merger filing (Jul 27, 2016)
- Business Wire - acquisition announcement
View network graph Full dataset JSON
Genomic HealthPrecision Medicine · Acquired by Exact Sciences (2019)
Oncotype DX genomic tests for breast, colon, and prostate cancer — used to guide chemotherapy decisions for early-stage breast cancer
Verified deal: acquired by Exact Sciences (2019-07-29) — ~$2.8B total consideration
Sources (2)
- Exact Sciences newsroom - press release (Jul 29, 2019)
- SEC EDGAR - merger proxy filing
View network graph Full dataset JSON
Foundation MedicinePrecision Medicine · Acquired by Roche (2018)
Comprehensive genomic profiling (CGP) for cancer — FoundationOne tests guide precision treatment including breast and ovarian cancer
Verified deal: acquired by Roche (2018-06-19) — $137/share for remaining shares (~$2.4B); total company value ~$5.3B fully diluted
Sources (5)
- Roche media release (Jun 19, 2018)
- Fierce Biotech - deal coverage
- SEC EDGAR - 10-K filing (CIK 0001573773, ticker FMI)
- Roche 8-K filing - acquisition announcement, 2018
- Company website - foundationmedicine.com
View network graph Full dataset JSON
Flatiron HealthPrecision Medicine · Acquired by Roche (2018)
Oncology-specific EHR and real-world evidence platform — 265+ community cancer clinics, data includes breast and ovarian cancer outcomes
Verified deal: acquired by Roche (2018-01-08) — ~$1.9B fully diluted, subject to adjustments
Sources (5)
- Roche media release (Apr 6, 2018)
- Flatiron Health company website
- Crunchbase - crunchbase.com/organization/flatiron-health
- Roche press release - acquisition announcement, 2018
- Company website - flatiron.com
View network graph Full dataset JSON
nVision MedicalDiagnostics · Acquired by Boston Scientific (2018)
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
Verified deal: acquired by Boston Scientific (2018-04-16) — $150M upfront + up to $125M in milestones over 4 years
Sources (2)
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
View network graph Full dataset JSON
GRAILPrecision Medicine · Acquired by Illumina (2021)
Multi-cancer early detection via blood-based screening (Galleri test) — uses cfDNA and machine learning to detect 50+ cancer types including breast and ovarian; spun out of Illumina
Verified deal: acquired by Illumina (2020-09-21) — $8B cash + stock; GRAIL stockholders also receive tiered revenue-based payments
Sources (3)
- Illumina press release (Sep 21, 2020)
- SEC EDGAR — Illumina merger filing
- GRAIL press release (Aug 18, 2021 — completion)
View network graph Full dataset JSON
CounsylDiagnostics · Acquired by Myriad Genetics (2018)
Prenatal and carrier genetic screening — Foresight carrier screen and Prequel NIPT (non-invasive prenatal testing); one of largest reproductive genetics labs in US
Verified deal: acquired by Myriad Genetics (2018-05-28) — ~$375M ($225M cash + $150M equity consideration)
Sources (2)
- Globe Newswire — Myriad Genetics press release (May 28, 2018)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Gateway GenomicsDiagnostics · Acquired by Myriad Genetics (2022)
Consumer genetic testing — SneakPeek early gender DNA test (detects baby gender at 6 weeks with 99% accuracy); 750K+ parents served, 20%+ CAGR
Verified deal: acquired by Myriad Genetics (2022-11-01) — $67.5M tuck-in acquisition (Myriad Genetics press release)
Sources (2)
- Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Invitae Reproductive HealthDiagnostics · Assets acquired by Natera (2024)
Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio
Verified deal: acquired by Natera (2024-01-22) — $10M upfront + up to $42.5M milestones (cash + litigation credits)
Sources (2)
- Business Wire — Natera press release (Jan 22, 2024)
- Natera investor relations
View network graph Full dataset JSON
SeagenPrecision Medicine · Acquired by Pfizer (2023)
Antibody-drug conjugate (ADC) oncology platform — Adcetris, Padcev, Tukysa (HER2+ breast cancer), and Tivdak (cervical cancer)
Verified deal: acquired by Pfizer (2023-03-13) — $229/share, ~$43B enterprise value
Sources (3)
- SEC EDGAR — Pfizer 8-K (Mar 13, 2023)
- Business Wire — Pfizer/Seagen merger announcement (Mar 13, 2023)
- SEC EDGAR — Pfizer 8-K completion (Dec 14, 2023)
View network graph Full dataset JSON
Varian Medical SystemsPrecision Medicine · Acquired by Siemens Healthineers (2021)
Radiation oncology and cancer treatment systems — linear accelerators, brachytherapy, and treatment planning software for breast, cervical, and other cancers
Verified deal: acquired by Siemens Healthineers (2020-08-02) — $177.50/share, ~$16.4B all-cash
Sources (3)
- Siemens Healthineers press release (Aug 2, 2020)
- PR Newswire — Varian merger announcement (Aug 2, 2020)
- SEC EDGAR — Varian DFAN14A (Aug 2020)
View network graph Full dataset JSON
Thrive Earlier DetectionDiagnostics · Acquired by Exact Sciences (2021)
Multi-cancer blood test (CancerSEEK) using cfDNA and protein biomarkers to detect multiple cancer types including breast and ovarian
Verified deal: acquired by Exact Sciences (2020-10-27) — ~$2.15B cash + stock
Sources (3)
- PR Newswire — Exact Sciences/Thrive announcement (Oct 27, 2020)
- PR Newswire — Exact Sciences completion (Jan 5, 2021)
- Milwaukee Business Journal (Jan 5, 2021)
View network graph Full dataset JSON
PreventionGeneticsDiagnostics · Acquired by Exact Sciences (2022)
CLIA-certified genetic testing laboratory — 5,000+ predefined tests for hereditary cancer (BRCA1/2, Lynch syndrome), carrier screening, and whole exome/genome sequencing
Verified deal: acquired by Exact Sciences (2022-01-09) — ~$190M (Laboratory Economics reporting)
Sources (3)
- PR Newswire — Exact Sciences press release (Jan 9, 2022)
- SEC EDGAR — Exact Sciences 8-K (Jan 10, 2022)
- Laboratory Economics — deal reporting (Jan 15, 2022)
View network graph Full dataset JSON
EUROIMMUNDiagnostics · Acquired by PerkinElmer (2017)
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
Verified deal: acquired by PerkinElmer (Revvity) (2017-06-16) — ~$1.3B cash
Sources (3)
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
View network graph Full dataset JSON
AlereDiagnostics · Acquired by Abbott (2017)
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
Verified deal: acquired by Abbott Laboratories (2016-02-01) — $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Sources (3)
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
View network graph Full dataset JSON
Gen-ProbeDiagnostics · Acquired by Hologic (2012)
Leader in molecular diagnostics including HPV/cervical cancer testing and STI screening
Verified deal: acquired by Hologic (2012-04-30) — Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
Sources (3)
- SEC EDGAR - Hologic 8-K/DEFM14A (2012)
- Hologic press release (August 1, 2012)
- Gen-Probe Incorporated SEC filings
View network graph Full dataset JSON
EvvyDiagnostics · Private (Series A)
At-home vaginal microbiome testing with metagenomic sequencing and precision treatment
No verified acquisition row for this company.
Sources (3)
- TechCrunch - $5M seed coverage (July 2021)
- Business Wire - $14M Series A announcement (September 2023)
- Fierce Healthcare - funding and STI care expansion coverage
View network graph Full dataset JSON
Testmate HealthDiagnostics · Private (Seed)
At-home rapid molecular STI test, starting with chlamydia and gonorrhea; $6M seed
No verified acquisition row for this company.
Sources (6)
- PRNewswire - $6M seed announcement (May 2024)
- Startupticker.ch - $6M seed coverage (May 2024)
- FinSMEs - seed round coverage (May 2024)
- GGBa - CHF 1.6M earlier financing coverage
- Crunchbase - crunchbase.com/organization/testmate-health
- Company website - testmatehealth.com
View network graph Full dataset JSON
Juniper GenomicsDiagnostics · Private (Seed)
Whole-genome and transcriptome embryo screening for IVF
No verified acquisition row for this company.
Sources (5)
- GenomeWeb - $4.6M seed launch coverage (June 2025)
- Femtech Insider - seed round coverage (2025)
- Future FemHealth - seed funding coverage (2025)
- Crunchbase - crunchbase.com/organization/juniper-genomics
- Company website - junipergenomics.com
View network graph Full dataset JSON
AOA DxDiagnostics · Private (Series B)
Glycolipid biomarker diagnostics for early ovarian cancer detection
No verified acquisition row for this company.
Sources (3)
- Endpoints News - $17M Series B; $24M total raised (October 2023)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - aoadx.com
View network graph Full dataset JSON
Eli HealthDiagnostics · Private
At-home saliva hormone monitoring with real-time insights
No verified acquisition row for this company.
Sources (3)
- Eli Health - total capital raised $20M (June 2025)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - eli.health
View network graph Full dataset JSON

Mismatch-repair genes (MLH1, MSH2, MSH6, PMS2) are associated with Lynch syndrome and increased endometrial and colorectal cancer risk. Access-equity framing requires separately sourced utilization data.

Disparity / prevalence (static)

Access and cascade-screening equity are research questions here; no quantitative disparity is promoted without a field-level citation.

Source: Illustrative research framing — use NCCN/ACMG sources before promoting a quantitative access claim

Verified portfolio overlap (Diagnostics, Precision Medicine, Breast Health) · 29 companies

BiotheranosticsBreast Health · Acquired by Hologic (2021)
Molecular diagnostic tests for breast and metastatic cancers (Breast Cancer Index, CancerTYPE ID)
Verified deal: acquired by Hologic (2021-01-05) — ~$230M subject to working capital adjustments
Sources (2)
- Hologic investor relations - press release (Jan 5, 2021)
- Business Wire - acquisition completion (Feb 22, 2021)
View network graph Full dataset JSON
EndomagneticsBreast Health · Acquired by Hologic (2024)
Magnetic marker and localization technology for breast cancer surgery (Magseed, Sentimag)
Verified deal: acquired by Hologic (2024-05-20) — ~$310M (Nasdaq/Hologic press release)
Sources (2)
- Nasdaq press release - Hologic acquisition (Jul 25, 2024)
- Endomagnetics company website - endomagnetics.com
View network graph Full dataset JSON
IgenomixDiagnostics · Acquired by Vitrolife (2021)
Global leader in reproductive genetic testing services for IVF clinics — preimplantation genetic testing across 26 countries
Verified deal: acquired by Vitrolife (2021-07-08) — Enterprise value ~€1.25B (~$1.45B); part cash, part share consideration
Sources (3)
- Cision/Vitrolife press release (Jul 8, 2021)
- PR Newswire - acquisition completion (Nov 30, 2021)
- EQT Group - sale announcement
View network graph Full dataset JSON
SequenomDiagnostics · Acquired by LabCorp (2016)
Pioneer in non-invasive prenatal testing (NIPT) — MaterniT21 test for fetal chromosomal abnormalities, over 500K tests performed
Verified deal: acquired by LabCorp (2016-07-27) — Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
Sources (2)
- SEC EDGAR - LabCorp/Sequenom merger filing (Jul 27, 2016)
- Business Wire - acquisition announcement
View network graph Full dataset JSON
Genomic HealthPrecision Medicine · Acquired by Exact Sciences (2019)
Oncotype DX genomic tests for breast, colon, and prostate cancer — used to guide chemotherapy decisions for early-stage breast cancer
Verified deal: acquired by Exact Sciences (2019-07-29) — ~$2.8B total consideration
Sources (2)
- Exact Sciences newsroom - press release (Jul 29, 2019)
- SEC EDGAR - merger proxy filing
View network graph Full dataset JSON
Foundation MedicinePrecision Medicine · Acquired by Roche (2018)
Comprehensive genomic profiling (CGP) for cancer — FoundationOne tests guide precision treatment including breast and ovarian cancer
Verified deal: acquired by Roche (2018-06-19) — $137/share for remaining shares (~$2.4B); total company value ~$5.3B fully diluted
Sources (5)
- Roche media release (Jun 19, 2018)
- Fierce Biotech - deal coverage
- SEC EDGAR - 10-K filing (CIK 0001573773, ticker FMI)
- Roche 8-K filing - acquisition announcement, 2018
- Company website - foundationmedicine.com
View network graph Full dataset JSON
Flatiron HealthPrecision Medicine · Acquired by Roche (2018)
Oncology-specific EHR and real-world evidence platform — 265+ community cancer clinics, data includes breast and ovarian cancer outcomes
Verified deal: acquired by Roche (2018-01-08) — ~$1.9B fully diluted, subject to adjustments
Sources (5)
- Roche media release (Apr 6, 2018)
- Flatiron Health company website
- Crunchbase - crunchbase.com/organization/flatiron-health
- Roche press release - acquisition announcement, 2018
- Company website - flatiron.com
View network graph Full dataset JSON
Focal TherapeuticsBreast Health · Acquired by Hologic (2018)
BioZorb implantable 3D marker for breast conserving surgery (lumpectomy) — marks tumor excision site for monitoring and treatment planning
Verified deal: acquired by Hologic (2018-09-26) — ~$125M cash (SEC filing shows $120.1M final purchase price)
Sources (2)
- Hologic investor relations press release (Sep 26, 2018)
- SEC EDGAR — Hologic 10-K FY2019 (purchase price $120.1M)
View network graph Full dataset JSON
nVision MedicalDiagnostics · Acquired by Boston Scientific (2018)
First FDA-cleared device for collecting cells from fallopian tubes — platform for earlier diagnosis of ovarian cancer; $500M near-term market opportunity estimated
Verified deal: acquired by Boston Scientific (2018-04-16) — $150M upfront + up to $125M in milestones over 4 years
Sources (2)
- PR Newswire — Boston Scientific press release (Apr 16, 2018)
- MassDevice deal coverage ($275M total)
View network graph Full dataset JSON
GRAILPrecision Medicine · Acquired by Illumina (2021)
Multi-cancer early detection via blood-based screening (Galleri test) — uses cfDNA and machine learning to detect 50+ cancer types including breast and ovarian; spun out of Illumina
Verified deal: acquired by Illumina (2020-09-21) — $8B cash + stock; GRAIL stockholders also receive tiered revenue-based payments
Sources (3)
- Illumina press release (Sep 21, 2020)
- SEC EDGAR — Illumina merger filing
- GRAIL press release (Aug 18, 2021 — completion)
View network graph Full dataset JSON
CounsylDiagnostics · Acquired by Myriad Genetics (2018)
Prenatal and carrier genetic screening — Foresight carrier screen and Prequel NIPT (non-invasive prenatal testing); one of largest reproductive genetics labs in US
Verified deal: acquired by Myriad Genetics (2018-05-28) — ~$375M ($225M cash + $150M equity consideration)
Sources (2)
- Globe Newswire — Myriad Genetics press release (May 28, 2018)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Gateway GenomicsDiagnostics · Acquired by Myriad Genetics (2022)
Consumer genetic testing — SneakPeek early gender DNA test (detects baby gender at 6 weeks with 99% accuracy); 750K+ parents served, 20%+ CAGR
Verified deal: acquired by Myriad Genetics (2022-11-01) — $67.5M tuck-in acquisition (Myriad Genetics press release)
Sources (2)
- Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
- Myriad Genetics investor relations
View network graph Full dataset JSON
Invitae Reproductive HealthDiagnostics · Assets acquired by Natera (2024)
Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio
Verified deal: acquired by Natera (2024-01-22) — $10M upfront + up to $42.5M milestones (cash + litigation credits)
Sources (2)
- Business Wire — Natera press release (Jan 22, 2024)
- Natera investor relations
View network graph Full dataset JSON
SeagenPrecision Medicine · Acquired by Pfizer (2023)
Antibody-drug conjugate (ADC) oncology platform — Adcetris, Padcev, Tukysa (HER2+ breast cancer), and Tivdak (cervical cancer)
Verified deal: acquired by Pfizer (2023-03-13) — $229/share, ~$43B enterprise value
Sources (3)
- SEC EDGAR — Pfizer 8-K (Mar 13, 2023)
- Business Wire — Pfizer/Seagen merger announcement (Mar 13, 2023)
- SEC EDGAR — Pfizer 8-K completion (Dec 14, 2023)
View network graph Full dataset JSON
Varian Medical SystemsPrecision Medicine · Acquired by Siemens Healthineers (2021)
Radiation oncology and cancer treatment systems — linear accelerators, brachytherapy, and treatment planning software for breast, cervical, and other cancers
Verified deal: acquired by Siemens Healthineers (2020-08-02) — $177.50/share, ~$16.4B all-cash
Sources (3)
- Siemens Healthineers press release (Aug 2, 2020)
- PR Newswire — Varian merger announcement (Aug 2, 2020)
- SEC EDGAR — Varian DFAN14A (Aug 2020)
View network graph Full dataset JSON
ImmunomedicsBreast Health · Acquired by Gilead Sciences (2020)
Developer of Trodelvy (sacituzumab govitecan), first-in-class Trop-2 ADC for metastatic triple-negative breast cancer (mTNBC)
Verified deal: acquired by Gilead Sciences (2020-09-13) — $88/share, ~$21B
Sources (3)
- Business Wire — Gilead/Immunomedics announcement (Sep 13, 2020)
- Gilead Sciences press release (Sep 13, 2020)
- SEC EDGAR — Immunomedics merger filing
View network graph Full dataset JSON
Thrive Earlier DetectionDiagnostics · Acquired by Exact Sciences (2021)
Multi-cancer blood test (CancerSEEK) using cfDNA and protein biomarkers to detect multiple cancer types including breast and ovarian
Verified deal: acquired by Exact Sciences (2020-10-27) — ~$2.15B cash + stock
Sources (3)
- PR Newswire — Exact Sciences/Thrive announcement (Oct 27, 2020)
- PR Newswire — Exact Sciences completion (Jan 5, 2021)
- Milwaukee Business Journal (Jan 5, 2021)
View network graph Full dataset JSON
PreventionGeneticsDiagnostics · Acquired by Exact Sciences (2022)
CLIA-certified genetic testing laboratory — 5,000+ predefined tests for hereditary cancer (BRCA1/2, Lynch syndrome), carrier screening, and whole exome/genome sequencing
Verified deal: acquired by Exact Sciences (2022-01-09) — ~$190M (Laboratory Economics reporting)
Sources (3)
- PR Newswire — Exact Sciences press release (Jan 9, 2022)
- SEC EDGAR — Exact Sciences 8-K (Jan 10, 2022)
- Laboratory Economics — deal reporting (Jan 15, 2022)
View network graph Full dataset JSON
EUROIMMUNDiagnostics · Acquired by PerkinElmer (2017)
Global leader in autoimmune diagnostics — extensive immunology, cell biology, and molecular biology capabilities; reproductive health channel drives into US market
Verified deal: acquired by PerkinElmer (Revvity) (2017-06-16) — ~$1.3B cash
Sources (3)
- SEC EDGAR — PerkinElmer 8-K (Jun 16, 2017)
- GenomeWeb — deal coverage (Jun 19, 2017)
- Revvity (PerkinElmer) investor relations — completion (Dec 19, 2017)
View network graph Full dataset JSON
Faxitron BiopticsBreast Health · Acquired by Hologic (2018)
Digital specimen radiography, breast lesion localization (LOCalizer), and sentinel lymph node biopsy solutions — VisionCT first 3D breast specimen CT system
Verified deal: acquired by Hologic (2018-07-31) — ~$85M (Hologic press release)
Sources (3)
- PR Newswire — Hologic press release (Jul 31, 2018)
- BioSpace — deal coverage (Jul 31, 2018)
- Hologic investor relations — SEC 10-K FY2019
View network graph Full dataset JSON
SuperSonic ImagineBreast Health · Acquired by Hologic (2019)
ShearWave elastography and Aixplorer ultrasound platform for breast cancer diagnosis — non-invasive tissue stiffness measurement for breast lesion characterization
Verified deal: acquired by Hologic (2019-06-21) — ~$85M total (€1.50/share equity + up to $43M debt payoff)
Sources (5)
- MassDevice — Hologic/SSI announcement (Jun 21, 2019)
- AuntMinnie — Hologic acquires 46% stake (Aug 4, 2019)
- Euronext Paris — SuperSonic Imagine (EPA: SSI) tender offer
- Crunchbase - crunchbase.com/organization/supersonic-imagine
- Hologic press release - acquisition announcement, 2019
View network graph Full dataset JSON
Sividon DiagnosticsBreast Health · Acquired by Myriad Genetics (2016)
EndoPredict breast cancer prognostic test — 12-gene RNA expression assay evaluating breast cancer aggressiveness; spun out of Siemens Healthcare Diagnostics
Verified deal: acquired by Myriad Genetics (2016-05-31) — €35M upfront + up to €15M performance milestones (~$56M total potential)
Sources (3)
- Globe Newswire — Myriad Genetics press release (May 31, 2016)
- SEC EDGAR — Myriad Genetics 8-K (May 31, 2016)
- GEN News — deal coverage (May 31, 2016)
View network graph Full dataset JSON
AlereDiagnostics · Acquired by Abbott (2017)
Global leader in point-of-care diagnostics — rapid tests for cardiometabolic, infectious disease, and toxicology; includes pregnancy and fertility testing portfolio
Verified deal: acquired by Abbott Laboratories (2016-02-01) — $51/share amended price, ~$5.3B equity value (reduced from original $5.8B)
Sources (3)
- SEC EDGAR — Abbott/Alere amended merger filing (Apr 14, 2017)
- Abbott Mediaroom — merger amendment (Apr 14, 2017)
- Abbott Mediaroom — closing confirmation (Sep 29, 2017)
View network graph Full dataset JSON
Gen-ProbeDiagnostics · Acquired by Hologic (2012)
Leader in molecular diagnostics including HPV/cervical cancer testing and STI screening
Verified deal: acquired by Hologic (2012-04-30) — Aggregate ~$3.7B including assumption of debt; $82.75/share cash tender
Sources (3)
- SEC EDGAR - Hologic 8-K/DEFM14A (2012)
- Hologic press release (August 1, 2012)
- Gen-Probe Incorporated SEC filings
View network graph Full dataset JSON
EvvyDiagnostics · Private (Series A)
At-home vaginal microbiome testing with metagenomic sequencing and precision treatment
No verified acquisition row for this company.
Sources (3)
- TechCrunch - $5M seed coverage (July 2021)
- Business Wire - $14M Series A announcement (September 2023)
- Fierce Healthcare - funding and STI care expansion coverage
View network graph Full dataset JSON
Testmate HealthDiagnostics · Private (Seed)
At-home rapid molecular STI test, starting with chlamydia and gonorrhea; $6M seed
No verified acquisition row for this company.
Sources (6)
- PRNewswire - $6M seed announcement (May 2024)
- Startupticker.ch - $6M seed coverage (May 2024)
- FinSMEs - seed round coverage (May 2024)
- GGBa - CHF 1.6M earlier financing coverage
- Crunchbase - crunchbase.com/organization/testmate-health
- Company website - testmatehealth.com
View network graph Full dataset JSON
Juniper GenomicsDiagnostics · Private (Seed)
Whole-genome and transcriptome embryo screening for IVF
No verified acquisition row for this company.
Sources (5)
- GenomeWeb - $4.6M seed launch coverage (June 2025)
- Femtech Insider - seed round coverage (2025)
- Future FemHealth - seed funding coverage (2025)
- Crunchbase - crunchbase.com/organization/juniper-genomics
- Company website - junipergenomics.com
View network graph Full dataset JSON
AOA DxDiagnostics · Private (Series B)
Glycolipid biomarker diagnostics for early ovarian cancer detection
No verified acquisition row for this company.
Sources (3)
- Endpoints News - $17M Series B; $24M total raised (October 2023)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - aoadx.com
View network graph Full dataset JSON
Eli HealthDiagnostics · Private
At-home saliva hormone monitoring with real-time insights
No verified acquisition row for this company.
Sources (3)
- Eli Health - total capital raised $20M (June 2025)
- RH Capital portfolio - rhcapital.vc/portfolio/
- Company website - eli.health
View network graph Full dataset JSON

Focus area	Data tier	Sample cos.	Source
Maternal mortality prevention	Cited epidemiology (static)	21	CDC/NCHS Maternal Mortality Rates in the United States, 2024 (published Mar 2026); CDC Maternal Mortality Review Committees, 2017–2019 preventability analysis
PCOS genetic markers	Cited epidemiology (static)	35	CDC, Diabetes and Polycystic Ovary Syndrome (PCOS), May 2024; WHO PCOS fact sheet for global prevalence context
Hereditary breast & ovarian cancer markers	Cited epidemiology (static)	29	American Cancer Society, Breast Cancer Facts & Figures 2024–2025; Cancer Statistics for African American/Black People, 2025
Sickle cell disease (HBB)	Cited epidemiology (static)	22	CDC Sickle Cell Disease data and surveillance; NHLBI sickle cell resources
Lupus / SLE genetic susceptibility	Cited epidemiology (static)	22	Lupus Foundation of America, Lupus Facts and Statistics and Health Disparities in Lupus
Lynch syndrome & multi-gene panels	Illustrative context only	29	Illustrative research framing — use NCCN/ACMG sources before promoting a quantitative access claim

Data compiled from public sources for educational visualization. Verify independently before any commercial use.

Patient empowerment (HLTH 2022)Impact Assessment (OAIS)Download deals CSV

Measuring What Matters

Cited burden and penetration context beside verified companies. No composite impact score, and no valuation inferred from a gap.

Opportunity Research

OAIS composite score withheld pending outcome calibration

Research-only framework. Lacuna previously combined epidemiology, penetration, stage, founder and scaling proxies into a 0–10 OAIS score. That composite is intentionally not displayed because its weights and thresholds have not been validated against observed investment or health outcomes. Inputs remain visible below for diligence; they should not be collapsed into a decision score.

Biotheranostics

Breast Health · Acquired by Hologic (2021)

Addressable population

4.1M

Range: 3.8–4.4M

Source: ACS Breast Cancer Facts & Figures 2024-2025; ACS Cancer Statistics for Black People (Feb 2025)

Penetration proxy

No mapped penetration proxy.

Verified market context

Other verified Lacuna companies in the same sector. This is dataset coverage, not total market competitor count.

Acquisition context

Hologic

Historical verified relationship only; not a prediction of future acquisition.

Unmeasured / proxy-dependent factors

Patient volume per company: Proprietary; companies do not disclose active patient counts pre-acquisition Proxy limitation: Overestimates if company has <1% market share; assumes average penetration
Clinical efficacy: Not published for most pre-acquisition startups; acquirers may keep data private Proxy limitation: Stage ≠ efficacy; late-stage companies can still fail in real-world settings
Patient outcomes post-acquisition: Outcomes data is private; HIPAA compliance; no public registry Proxy limitation: Past performance ≠ future results; each acquisition is different
Counterfactual impact: Cannot observe "what if this company never existed?" Proxy limitation: OAIS captures opportunity, not attributable impact
Scale-up multiplier: Post-acquisition patient growth is rarely disclosed Proxy limitation: Assumes acquirer applies same strategy; market conditions change

Promotion gate: a composite opportunity score should return only after its component definitions are source-resolved, confidence is computed from actual evidence classes, and thresholds are calibrated on held-out or observed outcomes. Until then, disagreement and missingness remain visible.

From Lab to Venture

Verified company name, sector, and stage for commercialization context. Report context is not turned into a company score.

Commercialization catalog

Verified company name, sector, and stage only. Stage, funding, and sector reports stay as context. They are not a readiness score, a clinical-validation claim, or an acquisition forecast.

Research integrity: context on this panel is not a score, a valuation, an acquisition prediction, or a market census.

Lacuna does not turn report context into a company score.
Lacuna does not turn a gap into a valuation.
Lacuna does not turn historical exits into an acquisition prediction.
Lacuna does not turn research representation into clinical validation.
Lacuna does not turn a qualitative expert assessment into an objective metric.
Lacuna does not turn unavailable data into 0.
Lacuna does not turn unknown into a negative finding.
Lacuna does not turn a static curated sample into a market census.
Lacuna does not turn AI opportunity framing into an AI performance claim.
Lacuna does not turn a polished dashboard into evidence that does not exist.

Sector context

Diagnostics and tools can address high-value clinical gaps, but reimbursement, adoption, clinical utility, and commercialization evidence remain key diligence considerations.

Sector context for diagnostics and tools. It does not assess the companies listed below.

Acessa Health

Gynecological Surgery · Acquired by Hologic (2020)

Alere

Maternal health text

Diagnostics · Acquired by Abbott (2017)

Alloy

Menopause · Private (Series A)

Alydia Health

Maternal health text

Maternal Health · Acquired by Organon (2021)

AOA Dx

Diagnostics · Private (Series B)

Aria CV

Medical Device · Private (Series B)

Attn: Grace

Pelvic Health · Private (Seed)

Béa Fertility

Fertility · Private (Seed)

Biotheranostics

Breast Health · Acquired by Hologic (2021)

Bolder Surgical

Gynecological Surgery · Acquired by Hologic (2021)

Bone Health Technologies

Medical Device · Private (Series A)

Cadence OTC

Reproductive Health · Private

Cat Health

Therapeutics · Private (Seed)

Celmatix

Fertility · Acquired by Gedeon Richter (2026)

Chronicle Bio

Tech Bio · Private (Seed)

Cirqle

Contraception · Private (Pre-Seed)

Clear Gene

Diagnostic (portfolio) · Private (Seed)

Cogentix Medical

Pelvic Health · Acquired by Laborie Medical (2019)

Contraline

Contraception · Private (Series B)

Cook Medical Reproductive Health

Fertility · Acquired by CooperSurgical (2022)

Counsyl

Diagnostics · Acquired by Myriad Genetics (2018)

Dermavant Sciences

Dermatology · Acquired by Organon (2024)

eFertility (STB Zorg)

Fertility · Acquired by Vitrolife (2024)

Eli Health

Diagnostics · Private

Endomagnetics

Breast Health · Acquired by Hologic (2024)

Estetra (Mithra assets)

Contraception · Acquired by Gedeon Richter (2024)

Ethicon GYNECARE TVT Products

Pelvic Health · Acquired by Caldera Medical (2025)

Eugin Group (North American operations)

Fertility · Acquired by IVI-RMA/KKR (2024)

EUROIMMUN

Diagnostics · Acquired by PerkinElmer (2017)

Everly Health

Diagnostic (portfolio) · Private (Series D)

Evvy

Diagnostics · Private (Series A)

Faxitron Bioptics

Breast Health · Acquired by Hologic (2018)

FemDx Medsystems

Medical Device · Private (Series A)

Flatiron Health

Precision Medicine · Acquired by Roche (2018)

Focal Therapeutics

Breast Health · Acquired by Hologic (2018)

Forendo Pharma

Reproductive Health · Acquired by Organon (2021)

Foundation Medicine

Precision Medicine · Acquired by Roche (2018)

Frontier Bio

Biotech · Private (Seed)

Future Family

Reproductive · Private (Series A)

Gameto

Biotech · Private (Series C)

Gateway Genomics

Diagnostics · Acquired by Myriad Genetics (2022)

Gen-Probe

Diagnostics · Acquired by Hologic (2012)

Generate Life Sciences

Reproductive Health · Acquired by CooperSurgical (2022)

Gennev

Menopause · Acquired by Unified Women's Healthcare (2022)

Genomic Health

Precision Medicine · Acquired by Exact Sciences (2019)

Gesynta Pharma

Reproductive Health · Private (Series B)

GRAIL

Precision Medicine · Acquired by Illumina (2021)

Granata Bio

Fertility · Private (Series A)

Gynesonics

Gynecological Surgery · Acquired by Hologic (2024)

Hamilton Thorne

Fertility · Acquired by Astorg (2024)

Harmony Nutrition

Biotech · Private (Seed)

Hera Biotech

Diagnostic (portfolio) · Private (Series A)

Igenomix

Diagnostics · Acquired by Vitrolife (2021)

Immunomedics

Breast Health · Acquired by Gilead Sciences (2020)

Indira IVF

Fertility · Majority stake acquired by BPEA EQT (2023)

Inherent Biosciences

Diagnostic (portfolio) · Private (Series A)

Invitae Reproductive Health

Diagnostics · Assets acquired by Natera (2024)

IVI-RMA Global

Fertility · Acquired by KKR (2023)

Juniper Genomics

Diagnostics · Private (Seed)

KaNDy Therapeutics

Menopause · Acquired by Bayer (2020)

Lighthouse Pharma

Therapeutics · Private (Seed)

Madorra

Medical Device · Private (Series A)

Mercy Bio

Diagnostic (portfolio) · Private (Series B)

Mirvie

Diagnostic (portfolio) · Private (Series C)

Myovant Sciences

Reproductive Health · Acquired by Sumitovant Biopharma (2023)

Nest Collaborative

Maternal health text

Maternal Health · Private (Seed)

Neuspera

Medical Device · Private (Series D)

Nine Continents Medical

Pelvic Health · Acquired by Coloplast (2020)

Novocuff

Maternal health text

Maternal Health · Private (Series A)

NowDx

Diagnostic (portfolio) · Private (Series A)

nVision Medical

Diagnostics · Acquired by Boston Scientific (2018)

obp Surgical

Gynecological Surgery · Acquired by CooperSurgical (2024)

Ocon Med

Reproductive Health · Private

Ogeda SA

Menopause · Acquired by Astellas (2017)

ORIGIO a/s

Fertility · Acquired by CooperSurgical (2012)

PreventionGenetics

Diagnostics · Acquired by Exact Sciences (2022)

Proov (portfolio)

Reproductive · Private (Series A)

Raydiant Oximetry

Maternal health text

Maternal Health · Private (Series A)

Sana Health

Medical Device · Private (Seed)

Seagen

Precision Medicine · Acquired by Pfizer (2023)

Sequenom

Diagnostics · Acquired by LabCorp (2016)

Siren

Medical Device · Private (Series B)

Sividon Diagnostics

Breast Health · Acquired by Myriad Genetics (2016)

Smith & Nephew Gynecology (Truclear)

Gynecological Surgery · Acquired by Medtronic (2016)

Solace Therapeutics

Medical Device · Private (Series B)

SuperSonic Imagine

Breast Health · Acquired by Hologic (2019)

Testmate Health

Diagnostics · Private (Seed)

TherapeuticsMD

Reproductive Health · Products licensed to Mayne Pharma (2023)

Thrive Earlier Detection

Diagnostics · Acquired by Exact Sciences (2021)

Toi Labs

Medical Device · Private (Seed)

Varian Medical Systems

Precision Medicine · Acquired by Siemens Healthineers (2021)

Veana Therapeutics

Therapeutics · Private (Seed)

Vitra Labs

Fertility · Private

Willow

Maternal health text

Maternal Health · Private (Series C)

X-Therma

Biotech · Private (Series B)

Xandar Kardian

Medical Device · Private (Series A)

xCures

Digital Health · Private (Series A)

YourChoice Therapeutics

Reproductive · Private (Series A)

ZyMōt Fertility

Fertility · Acquired by CooperSurgical (2024)

Burden–Capital Opportunity Context

Burden–Capital Opportunity Context

Stage funding median

Burden–Capital Opportunity Context

Context inputs

Endometriosis & Pelvic Pain

Dataset stage funding median

Context factors

Women's health exit landscape

Women's health exit landscape (macro research)

RH Capital portfolio

RH Capital portfolio (Foreground Capital)

Space research → trial → transaction

Space → trial → transaction gaps

Pipeline funnel (furthest stage)

Gap matrix (assets reaching stage)

Gap analyst (LLM)

Clinical Trials Worth Watching

Clinical Trial Tracker

Domestic research sample universe

Registry fields

Registry fields on verified targets

Disease-linked genetic markers

Patient empowerment baseline

Patient empowerment baseline (breast cancer, 2022)

Gap analyst (LLM)

Genetic Markers & Health Equity

Health equity context

Maternal mortality prevention

PCOS genetic markers

Hereditary breast & ovarian cancer markers

Sickle cell disease (HBB)

Lupus / SLE genetic susceptibility

Lynch syndrome & multi-gene panels

Measuring What Matters

Opportunity Research

Biotheranostics

Unmeasured / proxy-dependent factors

From Lab to Venture

Commercialization catalog

Acessa Health

Alere

Alloy

Alydia Health

AOA Dx

Aria CV

Attn: Grace

Béa Fertility

Biotheranostics

Bolder Surgical

Bone Health Technologies

Cadence OTC

Cat Health

Celmatix

Chronicle Bio

Cirqle

Clear Gene

Cogentix Medical

Contraline

Cook Medical Reproductive Health

Counsyl

Dermavant Sciences

eFertility (STB Zorg)

Eli Health

Endomagnetics

Estetra (Mithra assets)

Ethicon GYNECARE TVT Products

Eugin Group (North American operations)

EUROIMMUN

Everly Health

Evvy

Faxitron Bioptics

FemDx Medsystems

Flatiron Health

Focal Therapeutics

Forendo Pharma

Foundation Medicine

Frontier Bio

Future Family

Gameto